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ABSTRACT 
Epigenetic deregulation has emerged as a driver in human malignancies. There is no 
clear understanding of the epigenetic alterations in hepatocellular carcinoma and of the 
potential role of DNA methylation markers as prognostic biomarkers. The analysis of tumor 
tissue from 304 patients with hepatocellular carcinoma treated with surgical resection 
allowed us to generate a methylation-based prognostic signature using a training-validation 
scheme. Methylome profiling was done with the Illumina HumanMethylation450 array, 
which covers 96% of known CpG islands and 485,000 CpG, and transcriptome profiling was 
performed with Affymetrix Human Genome U219 Plate and miRNA Chip 2.0. Random 
Survival Forest enabled us to generate a methylation signature based on 36 methylation 
probes. We computed a risk score of mortality for each individual that accurately 
discriminated patient’s survival both in the training set (221 patients; 47% hepatitis C-related 
hepatocellular carcinoma) and validation sets (n=83; 47% alcohol-related hepatocellular 
carcinoma). This signature correlated with known predictors of poor outcome and retained 
independent prognostic capacity of survival along with multinodularity and platelet count. 
The subset of patients identified by this signature was enriched in the molecular subclass of 
proliferation with progenitor cell features. The study confirmed a high prevalence of genes 
known de-regulated by aberrant methylation in hepatocellular carcinoma (e.g. RASSF1, 
IGF2, APC) and other solid tumors (e.g. NOTCH3), and describe potential candidate 
epidrivers (e.g. SEPT9, EFNB2). Conclusions: A validated signature of 36 DNA methylation 
markers accurately predicts poor survival in patients with hepatocellular carcinoma. Patients 
with this methylation profile harbor mRNA-based signatures indicating tumors with 
progenitor cell features. 
   
 
 
Keywords: Liver cancer; epigenetics; biomarker.
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INTRODUCTION 
Liver cancer represents a major health problem being the second cause of cancer death 
worldwide
1
. The disease burden of this malignancy continues to grow and it is a leading 
cause of disability
2
. Surgical resection, liver transplantation and local ablation are the 
recommended treatment options for early hepatocellular carcinoma (HCC), but can only be 
applied to around 30% of patients in the West. Current clinical practice guidelines 
recommend resection in patients with single tumors and well-preserved liver function
3,4
. Even 
in these cases, tumor recurrence occurs in up to 70% of patients at 5 years, and no adjuvant 
therapy is presently available. Recent studies demonstrate how mRNA-based gene signatures 
obtained from HCC resection specimens and biopsies improve prognostic performance of 
conventional clinical and pathological variables
5-7
. Direct translation of these prognostic 
signatures into clinical decision-making has not yet occurred. Further understanding of 
tumour biology in HCC is needed to optimize prognostic accuracy and improve trial design 
and clinical management.  
DNA methylation regulates cell differentiation and participates in tumorigenesis
8
. 
Global loss of DNA methylation is a hallmark of human cancer, also characterized by 
selective hyper-methylation confined to gene promoters. Solid evidence indicates that 
epigenetic marks could be used as prognostic and predictive biomarkers in oncology
9
. 
Analysis of methylomes enabled classification of colorectal carcinoma patients based on their 
prognosis
10
. In HCC, there is no clear understanding of the methylome and epidrivers, and 
few studies have comprehensively evaluated methylation biomarkers using high-throughput 
platforms
11
. Herein, using genome-wide methylation profiling we introduce and validate a 
36-probe methylation signature able to accurately predict survival in HCC patients, and 
describe the landscape of aberrant methylation of key potential tumors suppressors and 
oncogenes in this cancer. 
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MATERIALS AND METHODS 
Human samples and molecular profiling 
Initially, study included samples from 331 surgically resected HCC and 19 non-tumor 
tissues including 9 cirrhosis and 10 normal livers. Training set (Heptromic dataset, n=248, 
flow chart in Suppl. Fig. 1) were samples obtained from two institutions of the HCC 
Genomic Consortium: IRCCS Istituto Nazionale Tumori, Milan (n=217) and Hospital Clínic, 
Barcelona (n=31). All samples included in this study were fresh-frozen. For RNA and DNA 
extraction we used the Qiagen RNeasy Mini (500 ng of total RNA at a concentration of 100 
ng/µL) and Invitrogen ChargeSwitch gDNA Mini Tissue (1 µg of total DNA at a 
concentration of 100 ng/µL) kits, respectively. The median sample storage time from 
collection to DNA/RNA extraction was 7 years. RNA profiling was conducted on 228 HCC 
and 168 non-tumor liver adjacent cirrhotic tissues using the Affymetrix Human Genome 
U219 Array Plate, which is able to interrogate more than 20,000 mapped genes. After 
hybridization, only one tumor sample was discarded for transcriptome analysis due to poor 
quality. Methylome profiling was performed on 248 samples with the Illumina Infinium 
HumanMethylation450 BeadChip array that interrogates more than 485,000 CpG sites 
covering 96% of known CpG islands
12
. Out of the 248 HCC samples from the training set, 
221 HCC qualified for final analyses after quality filtering (i.e., less than 5% of the probes 
incorrectly interrogated (p-value < 0.01)). In 205 patients, there was information on both 
transcriptome and methylation profiling. For the validation of the methylation-based 
signature, we analyzed data from a cohort of 83 HCC patients treated with resection in two 
French institutions (Bordeaux and Créteil hospitals), profiled with the same technology as the 
training set. The Institutional Review Boards of the participating centers approved the study.  
Pyrosequencing validation 
DNA methylation was evaluated with a pyrosequencing assay in a subset of samples 
previously analyzed by the Illumina Infinium Human Methylation450 array. A minimum of 
500 ng of DNA was converted using the EZ DNA Methylation Gold (Zymo Research) 
bisulfite conversion kit following the manufacturer’s recommendations. Specific sets of 
primers for PCR amplification and sequencing were designed using specific software 
(PyroMark assay design version 2.0.01.15). These are summarized in Suppl. Table 1. Primer 
sequences were designed, when possible, to hybridize with CpG-free sites to ensure 
methylation-independent amplification. PCR was performed under standard conditions with 
biotinylated primers, and the PyroMark Vacuum Prep Tool (Biotage, Sweden) was used to 
prepare single-stranded PCR products according to manufacturer’s instructions. PCR 
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products were observed at 2% agarose gels before pyrosequencing. Reactions were 
performed in a PyroMark Q96 System version 2.0.6 (Qiagen) using appropriate reagents and 
protocols. 
Data analysis 
To study differential methylation between HCC and normal liver tissue, probes 
containing SNPs or located on sex chromosomes were eliminated, leaving 434,728 probes for 
analysis. Only those with a high signal quality (P<0.01) were considered. Probes hypo-
methylated (B<0.33) in at least 90% of the normal liver samples and hyper-methylated 
(B>0.5) in at least 5% of the tumors (31,052 CpG sites) and probes hyper-methylated (B>0.5) 
in at least 90% of the normal liver and hypo-methylated (B<0.33) in at least 5% of the tumors 
were selected (68,086 CpG sites). The beta value (B) is used to estimate the methylation level 
of the CpG locus using the ratio of intensities between methylated and unmethylated alleles. 
For prognosis purposes, analyses focused only on CpGs islands located in TSS1500, TSS200, 
5’UTR and 1stExon (n=84,448) shown to be differentially methylated in tumors versus 
normal liver according to predefined criteria (n=11,307)
13
. This enabled us to select for those 
methylation markers primarily de-regulated in cancer tissues.  
In order to discover potential candidate HCC epidrivers, an F score directly 
proportional to intergroup variability (normal liver versus HCC) and inversely proportional to 
normal sample intragroup variability was calculated for all probes located in promoters and 
CpG islands. The first 500 ranked probes were grouped per gene. Genes with more than 5 hits 
were further studied as epidrivers. Previously reported epigenetically deregulated genes were 
also analyzed, considering the mean of all probes located in the TSS200 region, which shows 
the best correlation with expression. For those samples without TSS200 probes in the array, 
TSS1500 were used instead, as the closest marker available in the array.  
We generate a methylome signature able to predict the risk of death for each individual 
measured by a mortality index (MI). The prediction signature was generated using the 
Random Survival Forest method (RSF) developed for variable selection
13
. RSF is a method 
for prediction and variable selection for right-censored survival and competing risk data by 
growing survival trees to estimate a cumulative hazard function (CHF), which derives from 
each tree of the RSF. Input variables were the filtered 11,307 CpG sites. First, probes were 
randomly split in 6 sets of 2,000 or less probes to fit a model each using the RSF method by 
growing 1,000 survival trees. Variable importance scores (VIMP) were computed for all the 
probes used to grow the trees, and the 350 most informative from each model were selected 
to fit a new model using the same RSF method. Once the model was built, we removed 
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redundant and “noisy” variables by generating incremental RSF models adding one more 
variable, ranked by the VIMP calculated in the previous model, at each step, getting an 
estimate of the error as a measure of how much misclassification increases, or decreases, for 
a new test case if a given variable was not available for that case. The final set of selected 
variables (36 probes) was used to build the model having the lowest error rate using only the 
2 most significant decimals of the obtained error rate. Thus, the methylation signature was 
based upon those 36 probes. The predictive accuracy of the 36-signature was examined by 
bootstrap cross-validation
13
. This allows estimating the prediction error curves of different 
survival models on 100 bootstrap samples, and comparing the performance of the different 
models (i.e., Cox and RSF) with a reference (estimation for the whole group without splitting 
based on the prediction variables, Suppl. Fig. 2).  
From the last RSF model, we generated a DNA methylation-based mortality risk score 
(i.e., Mortality Index, range 36-360) for every individual computed as a sum of the CHF for 
each patient evaluated at a set of distinct time points weighed by the number of individuals at 
risk at the different time points. High mortality index (MI) correlates with higher risk of 
death. Using this index, we were able to split our training set in 2 risk groups based on 
percentiles, selecting the patients with the 20% highest levels [high risk (MI>230) and non-
high risk (MI<230)] and test the variables selected as a prediction signature by confronting 
the high and low risk groups. To test the significance of the MI index, the same MI value 
used to split the training set was also used for the validation set. In other words, for the 
validation we didn’t used percentiles, and split patients using the actual same value of the MI 
generated in the training set.  
Processing of transcriptome data (i.e., normalization, background correction and 
filtering) was conducted as previously reported
5
. Prediction of liver cancer mRNA-based 
signatures in the training set was performed using the Nearest Template Prediction (NTP) 
method as implemented in the specific module of Gene Pattern software
14
. All mRNA 
signatures analyzed were already reported, being deposited in the Molecular Signature 
Database (www.broadinstitute.org/gsea/msigdb). To provide biological insight on samples 
with high mortality risk score (>230, percentile 80), we used the Gene Set Enrichment 
Analysis (GSEA) as implemented in Gene Pattern. Gene ontology by PANTHER, 
INTERPRO and KEGG pathways enrichment analysis was performed using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID; v6.7). 
Outcome analyses were framed within current guidelines from the Progress Partnership 
for prognostic factor research
15
. Kaplan-Meier plots and Cox regression were used to assess 
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association with outcome of the methylation signature and clinical variables. Overall survival 
was defined as the time between surgical resection and death of any cause or last follow-up, 
whereas cancer-related survival (validation set) was the time between resection to HCC-
related death, as previously defined
16
. Time to recurrence is the time between resection and 
the radiological evidence of first tumor recurrence. Several clinical variables previously 
reported as outcome predictors in HCC were included in the analysis: gender, age, etiology of 
liver disease, tumor size, serum albumin, serum bilirubin, platelet count, serum AFP, BCLC 
stage
17
, microvascular invasion, satellites, degree of differentiation . Variables with a p-value 
less than 0.05 in the univariate analysis (log-rank test) were separately evaluated in a 
multivariate Cox model aimed to identify independent predictors of survival and recurrence. 
Missing values were less than 10% for each variable included in the Cox model. Analyses 
were performed using the GenePattern analytical toolkit 
(www.broad.mit.edu/cancer/software/genepattern/), and the R statistical package (www.r-
project.org). 
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RESULTS 
Methylation signature predicts survival in hepatocellular carcinoma 
Random survival forests enabled us to generate a methylation-based signature that 
accurately discriminated patients based on their survival (Training set, n=221). Table 1 
summarizes the clinical characteristics of this cohort, that mostly included males (172, 78%), 
with a median of 66 years/old, viral-related HCC (HCV: 101,47%, HBV: 44, 20%), and a 
median tumor size of 3.5 cm. Patients had predominantly uninodular disease (166, 75%), and 
no microvascular invasion (142, 65%) or satellites (158, 71%), being the majority at early 
clinical stages (BCLC O/A: 191, 87%) with a median follow-up of 48.5 months. Using the 
array data, we generated a methylation-based signature formed by 36 unique probes (Suppl. 
Table 2) that enable us to provide a DNA-methylation-based risk score of mortality 
(mortality index, ranging from 36-360, Fig. 1A). As predicted, these 36 probes were hyper-
methylated in tumor compared to non-tumor tissue (Suppl Fig 3). To ensure reproducibility 
of the methylation status of these probes, we performed technical validation and determine 
methylation levels by pyrosequencing in a subset of 10 probes in 20 HCC. As show in Suppl. 
Fig 4 there was a significant and high concordance on the methylation status of these probes 
using both methods.  
The mortality index is a metric based on the weighed hazard of death for an individual 
across all trees (see methods for details). This DNA methylome-based score of mortality risk 
significantly correlated with known clinical and pathological predictors of survival, such as 
satellites (P=0.02), multinodularity (P=0.002), vascular invasion (P<0.001), BCLC staging 
(P=0.001), AFP (P=0.001), bilirubin (P=0.01), platelet count (P=0.009) and albumin (P=0.03, 
Fig. 1B-I). Concordantly, univariate analysis showed that DNA-methylation mortality index 
significantly correlated with risk of death (P<0.001, Fig. 2A). Median survival was 
significantly lower for patients with DNA-methylation MI> 230 – which represent 20% of 
the cohort – than for those with MI<230 (13 vs 79.7 months, respectively P<0.001) (Fig. 2B). 
Multivariate Cox modeling confirmed DNA-methylation-MI as an independent predictor of 
survival (HR: 13.35, 95% CI 7.94-22.42, P<0.001) along with multinodularity (HR: 1.65, 
95% CI 1.03-2.62, P<0.001) and platelet count (HR: 1.58, 95% CI 1.01-2.41, P=0.03, Table 
2). Similarly, DNA-methylation-MI score predicted tumor recurrence (Fig. 2C) and Cox 
modeling showed that the signature was also an independent predictor of overall recurrence 
(HR: 5.8, 95% CI 3.1-11, P<0.001) along with multinodularity (HR: 1.8, 95% CI 1.1-3, 
P=0.007, Table 2). 
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We next sought to validate the prognostic performance of our methylation-based MI in 
an independent dataset. The validation cohort also included 83 HCC patients treated by 
surgical resection from different French institutions. Unlike the training set, the main etiology 
of these patients was related to alcohol intake (47%, 39/83), presented with more aggressive 
disease (microvascular invasion 54%, satellites 42% and tumors >3cm in 83%) and had 
shorter median follow-up time (35 months). Patients with a high DNA-methylation-based MI 
had a significantly lower cancer-related survival (P=0.01, Fig. 2D). Even when arbitrary 
categorizing MI by percentiles, there is a direct relation between MI and poor outcome, both 
in training and validation sets (Suppl. Fig. 5). Overall, these data demonstrates how 
epigenetic de-regulation correlates with patient outcome in surgically resected HCC and 
introduces a first-in-class DNA validated methylation-based signature.  
 
Integrated prognostic classification with transcriptome-based predictors 
In order to further characterize the subset of patients identified by the DNA-
methylation signature, we integrate whole-genome mRNA and methylation data of 205 
HCCs. DNA-methylation-based high mortality index was significantly enriched in tumors 
that harbored mRNA signatures capturing progenitor cell features such as EpCAM
18
 
(P=0.009) and S2 (a reported molecular class of potential progenitor cell origin)
19
 (P=0.006, 
Fig. 3). This was further confirmed when we performed GSEA on the samples with the 
highest MI (Suppl. Table 3). In addition, we found a significant enrichment of Gene 
Ontologies related to chromosomal dynamics and RNA processing in these samples 
(FDR<0.05). Conversely, tumors with DNA-methylation-based low MI were enriched in 
gene sets associated with metabolism and homeostasis (Suppl. Table 3).  
Non-coding mRNA expression profile and DNA methylation data were tested in 205 
samples. Patients with a high DNA-methylation MI had a differential non-coding mRNA 
expression pattern comprising 5 miRNAs and 1 small nucleolar RNA: miR-3193 (P<0.001), 
miR-27b-star (P=0.002), miR-422a (P=0.02), miR-378c (P=0.03), miR-938 (P=0.03) and 
SNORD126 (annotated as miR-1201 in the array) (P=0.03). All 6 non-coding RNAs were 
significantly down regulated in patients with DNA-methylation high MI score (Suppl. Fig. 
6).  
 
Aberrant methylation in human HCC 
Similarly to other malignancies, there was a remarkable predominance of hypo-
methylated probes in HCC compared to normal liver (68%, Fig. 4A). Hypo-methylated 
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probes were mainly located in the intergenic (39.9%) and body regions (34.5%), whereas 
hyper-methylated probes were predominantly located in promoter areas (50.5%). Regarding 
CpG island relation, hypo-methylated probes were mainly located in open sea regions 
(63.55%), while hyper-methylated probes tended to locate in CpG islands (63.9%) and shores 
(24.8%) (Fig. 4A).  
To identify potential methylation markers of malignant transformation, we searched for 
probes that could accurately differentiate normal liver tissue and HCC, among the 11,307 
above described probes. Analyses focused on probes with low intra-group variability (tumor 
and non-tumor) but high inter-group variability as defined by an F score (mean-β differences 
between groups / mean-β differences within groups). The top-100 ranked probes using this 
score, were able to accurately differentiate normal liver and HCC tissues (Fig. 4B, Suppl. 
Table 4). These 100 probes were all hyper-methylated in HCC and corresponded to 70 
different genes. Gene ontology analyses showed enrichment in entries related to gene 
expression regulation (such as transcription factors (P=2.9E
-6
)), and different signaling 






) and cadherin (p=3.5E
-2
), 
among others. When compared to a recently published analysis in 24 HCC
20
, we found 43 
common probes (Suppl. Fig 7A, Suppl. Table 5), and validated their ability to distinguish 
HCC from non-tumor tissue (Suppl. Fig 7B).  
We next sought to explore the landscape of known and novel genes candidates as 
potential epidrivers in HCC. First, we validated other previously reported aberrantly DNA 
methylated genes in HCC such as hyper-methylation of RASSF1 (82%), APC (78%) or NEFH 
(43%)
21
 and hypo-methylation of IGF2 (51%), among others (Table 3). Then, we identified 





 and ZIC1. Finally, in order to describe novel candidate potential 
epidrivers not previously described in HCC, we selected the top 500 F-scored probes that 
were clustered in their target genes (Suppl. Table 6), and identified genes involved in TGFB, 
or FGF signaling. Those genes with the highest number of de-regulated hits between HCC 
and normal liver were highlighted as the most appealing candidates (Table 3). Some of these 
candidates were also validated with pyrosequencing (Suppl. Fig. 8). Among them SEPT9, a 
tumor suppressor described in colon and ovarian cancer
23
, and ephrin-B2 ligand EFNB2, 
which hyper-methylation was reported in patients with acute leukemia
24
. These new 
candidate epidrivers were also found significantly de-regulated in the validation cohort of 83 
HCCs (Fig. 5).  
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DISCUSSION 
The understanding of molecular pathogenesis of HCC and gene-based prognostic 
prediction has improved during the last decade. By using next generation sequencing and 
SNP array analysis the main structural alterations and drivers in HCC have been uncovered. 
Similarly, transcriptome analysis allowed establishing molecular subclasses of this cancer, 
although with no direct implications in the management of patients so far
11
. Nonetheless, 
there still is a clear lack of understanding of the role of epigenetics in HCC and whether 
parameters related to methylation have clinical and outcome relevance. Few studies have 
addressed the role of epigenetics in hepatocarcinogenesis
20,25,26
, and there is even less 
information regarding the relevance of DNA-methylation based signatures as prognostic 
biomarkers of this prevalent and lethal cancer. Herein, by using a genome-wide approach, we 
present a first in class 36-probe DNA methylation signature able to characterize a molecularly 
aggressive HCC subtype. In addition, we describe a landscape of aberrantly methylated 
promoters of genes potentially involved in hepatocarcinogenesis. 
To develop the signature, we profiled a total of 304 HCCs (221 in training and 83 in 
validation sets) using high-density methylation arrays in a training-validation approach. 
Previous studies have looked at epigenetic prognostic markers in HCC, but using lower 
density arrays, less samples and without independent validation
20,26,27
. Similarly to other solid 
tumors
8
, our study demonstrates the capability of methylation data to accurately classify HCC 
patients based on their outcome. Unlike previous prediction methods applied in prognostic 
studies in HCC
5
, the design of the 36-probe signature provides a quantitative death risk score 
(i.e., mortality index) to each new patient eliminating signal redundancy. Correlation with 
other prognostic clinical parameters in the training set reinforces its prognostic performance. 
Of note, despite remarkable etiology differences between the training (mostly hepatitis C) 
and validation (mainly alcohol related) sets, the signature confirmed its ability for outcome 
prediction. In addition, the DNA-methylation signature defines high risk of mortality in 20% 
of patients in the cohort with best outcome (i.e., training set), compared to 50% of patients in 
the validation cohort, proved to have more aggressive tumors, a feature that suggests the 
ability of the DNA-methylation signature to identify patients with aggressive tumors across 
different stages.   
Frequently, prognosis research studies lack the high standards required in other fields of 
medicine such as therapeutic trials and genetic epidemiology
28
. This is paradigmatic in 
prognostic gene signatures considering the high discrepancy between reported ones and those 
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that are finally implemented in clinical practice. In fact, currently guidelines in HCC 
management do not include any of such in the routine care of HCC patients
3,4
. Our study is 
entirely consonant with the prognostic factor research scheme of the PROGESS 
Partnership
28
, an initiative that builds upon previous recommendations for reporting 
prognostic biomarkers in oncology (REMARK statement
29
). Nonetheless, in order to confirm 
the clinical strength of the novel information obtained with the DNA-methylation signature, 
an external independent validation would be required to conform to recent guidelines in 
HCC
3
. In terms of its clinical implementation, prospective validation of the signature in 
cohort studies will provide solid evidence to facilitate its inclusion in clinical practice 
guidelines. Preliminary studies suggest the feasibility of DNA methylation profiling from 
biopsy specimens or even plasma (i.e., circulating cell-free DNA)
30
. 
Integrative analysis with transcriptome data enabled us to obtain additional insight into 
molecular subclasses in HCC. Considering that DNA methylation provides one of the layers 
of epigenetic control of tissue specification and differentiation
31
, it is remarkable that patients 
within the high mortality risk group based on the methylation signature (defined by a 
mortality index higher than 230) were significantly enriched in mRNA proliferation 




).  Interestingly, we found a 
set of non-coding RNA significantly down-regulated in patients within the high-risk 
methylation group. Of note, miR-27b has been characterized as a regulatory hub in lipid 
metabolism in liver
32
, being also involved in PPAR signaling
33
. The role of the PPAR 
receptors in HCC remains controversial
34
, but in retrospective studies the use of PPARγ 
agonists was associated with a decrease in liver cancer
35
.  
 Around 140 genetic drivers have been described in oncogenesis
36
, among which 
epidrivers are the most unknown category. We describe a landscape of DNA-methylation 
aberrations in 221 HCC patients using a last generation technology. Our findings point to 
IGF, PI3K, TGF-B and WNT signaling as the pathways clearly deregulated by DNA 
methylation in HCC. We also explored the role of methylation in WNT signaling in a subset 
of 47 samples for which we had CTNNB1 mutation status data. Interestingly, we found 
significant hyper-methylation of the 4 WNT pathway genes included among the top-500 F-
scored probes in CTNNB1 mutated samples (12/47, 25%) compared to wild type (P<0.05, 
Suppl Fig 9). Whether epigenetic changes contribute to further de-regulate WNT signaling in 
addition to CTNNB1 mutations deserves additional investigations. We confirm the high 
prevalence of DNA-methylation aberrations of promoters of described tumor suppressors 
(RSSFA1, APC, NEFH)
21
 or potential oncogenes (IGF2) in HCC. On the other hand, we 
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identified aberrant methylation in HCC of epidrivers described in other neoplasms, such as 
NOTCH3 in acute leukemias
37
, NSD1 in glioblastoma
38
 and ZIC1 in colorectal cancer
39
. 
Finally, we are pointing to novel candidates that despite being involved in carcinogenesis, 
have not been described as de-regulated by DNA methylation, such as SEPT9, a tumor 
suppressor described in colon and ovarian cancer, and ephrin-B2 ligand EFNB2, which 
hyper-methylation was reported in patients with acute leukemia, and others involved in TGF-
B receptor signaling pathway (HOXA9, FOXG1 and RUNX3) and FGF-signaling pathway 
(FGF8 and FGF6). This novel information provides a complementary portrait of epigenetic 
changes in HCC. 
In summary, we describe a novel prognostic biomarker based on promoter DNA 
methylation changes in HCC that identifies patients at high risk of death and provides 
complementary epigenetic characterization of this tumor. Early detection of ‘poor biology’ 
HCCs could have a major impact in the decision-making and allocation of resources such in 
the adjuvant setting or complex therapies, such as resection or transplantation. In addition, 
potential candidate epidrivers have been described in HCC, which would require functional 
studies for biological confirmation.  
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FIGURE LEGENDS 
Figure 1: Distribution of DNA-methylation-derived mortality index in the training set 
(Heptromic) as per density plot (A). Boxplots (with over-imposed individual values) for 
different clinical and pathological variables known to be prognostic in HCC and the mortality 
index (B-I) 
Figure 2: Predicted hazard ratio for survival based on DNA-methylation-derived 
mortality index values (A). Kaplan-Meier plots for outcome analysis in Heptromic (n=221, 
training, B-C) and French datasets (n=83, validation, D) 
Figure 3: Boxplots (with over-imposed individual values) of mortality index according 
to S and EpCAM mRNA-based molecular subclasses (A). Patients in the S2 and EpCAM 
classes (reported initially as identifying tumors with a progenitor cell origin) have significant 
higher levels of DNA-methylation-derived MI based on predictions from the methylation 
signatures.  (B) Bottom panel represents enrichment of the 205 samples with methylation and 
mRNA data based on the levels of risk from the MI score. Top 20% patients with the highest 
DNA-methylation-derived MI score are significantly enriched in S2 and EpCAM classes 
Figure 4: Genome-wide DNA methylation profiling of HCC patients. Genomic 
distribution of the differentially methylated probes between normal liver and HCC samples 
according to: i) functional genomic distribution (promoter, body, 3´UTR and intergenic) and, 
ii) CpG content and neighborhood context (island, shore, shelf and open sea) (A). 
Unsupervised hierarchical clustering of 10 normal liver (yellow), 9 cirrhotic liver (orange) 
and 221 HCC samples (blue) using the top 100 differentially methylated probes according to 
F score (B). 
Figure 5: (Left panels) Boxplots represent de-methylation status of new candidate 
epidrivers generated from the training cohort (Heptromic). Right panels show their values on 
the French cohort (validation). P-values computed comparing HCC versus normal liver.  
 
Supplementary figure 1: Flow chart summarizing the HCC samples profiled for this 
study. 
Supplementary figure 2: Predictive accuracy of the 36-probe signature. Estimation of 
the prediction error based on 100 bootstrap samples and comparing the performance of Cox 
modeling and RSF versus a reference model. The reference is a simplification that estimates a 
survival curve for the whole set (Heptromic cohort) without splitting using the predictor 
variables.  
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Supplementary figure 3: Methylation status of the 36 CpG probes of the DNA 
prognostic methylation signature in HCC versus non-tumor tissue. Analysis was performed in 
samples from the training set. In brackets, P-values computed from one-way ANOVA of 
comparing ß-values in the three groups (normal liver, cirrhosis and HCC). 
Supplementary figure 4: Technical validation of the DNA methylation signature. A 
subset of 10 probes from the 36-probe signature was analyzed in 20 HCC fresh-frozen 
samples from the training set using pyrosequencing. DNA methylation results based on 
Illumina 450K array data (y-axis) and pyrosequencing (x-axis) are plotted for each of the 10 
probes tested. R represents Pearson’s coefficient. 
Supplementary figure 5: Kaplan-Meier curves of training and validation sets for 
different categorization values of the MI (tertiales, quartiles, quintiles and sextiles). Since the 
validation set has more advanced tumors, the proportion of patients in low percentiles is low. 
For each category, there is a dose-dependent effect between MI level and outcome.  
Supplementary figure 6: Boxplots (with over-imposed individual values) for 
expression levels of miRNAs differentially expressed after characterization in low-mid MI 
(MI<230) and high MI (MI>230) subgroups (t-test p-values corrected by FDR reported). 
Supplementary figure 7: Overlap of significant de-methylation probes in our dataset 
compared with previous studies. Panel A shows a Venn diagram with the 43 common 
differentially methylated probes in our study compare to the ones found by Song et al
20
. 
These 43 probes are depicted in Suppl. Table 5. Panel B shows the resulting heatmap after 
supervised clustering of the samples in our training set (n=221) using these 43 overlapped 
probes.  
Supplementary figure 8: Technical validation of novel epidrivers. A set of 4 candidate 
epidrivers was analyzed in 10 HCC and 10 non-tumor fresh-frozen samples from the training 
set (5 normal liver and 5 cirrhotics) using pyrosequencing.  DNA methylation results based 
on Illumina 450K array data (y-axis) and pyrosequencing (x-axis) are plotted for each of the 
candidate. Dots are colored based on the sample type (HCC, cirrhosis or normal liver). R 
represents Pearson’s coefficient. 
Supplementary figure 9: Methylation status of WNT pathway genes in samples 
according to their CTNNB1 mutation status (sub-analysis conducted in 47 samples of the 
training set). 
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TABLES 
 Table 1: Clinical characteristics of HCC patients in the training and validation set. 
  Variable Training (n=221) Validation (n=83) 
     
 Median age 66 66 
     
 Gender (male) 172 (78%) 68 (81%) 
     
 Aetiology   
  Hepatitis C 101 (47%) 9 (11%) 
  Hepatitis B 44 (20%) 17 (20%) 
  Alcohol 35 (16%) 39 (47%) 
  Others 37 (17%) NA 
     
 Child-Pugh score:    
  A 216 (96%) 74 (92%) 
  B 4 (2%) 9 (8%) 
     
 Tumour size (cm)   
  <2 26 (11%) 5 (6%) 
  2-3 73 (33%) 9 (11%) 
  >3 122 (55%) 69 (83%) 
     
 Multiple nodules   
  Absent 166 (75%) 69 (84%) 
  Present 55 (25%) 16 (16%) 
     
 Micro-vascular invasion   
  Absent 142 (64%) 38 (46%) 
  Present 77 (35%) 44 (54%) 
     
 Satellites   
  Absent 158 (71%) 48 (58%) 
  Present 63 (29%) 35 (42%) 
     
 BCLC early stage (0-A) 191 (87%) 59 (73%) 
     
 Degree of tumour differentiation  
  Well 34 (18%) 28 (34%) 
  Moderately 105 (57%) 35 (43%) 
  Poor 45 (24%) 19 (23%) 
     
 Bilirubin (>1 mg/dL) 92 (42%) 10 (19%)† 
     
 Albumin (<3.5 g/L) 25 (11%) NA 
     
 Platelet count (<100,000/mm3) 43 (19%) NA 
     
 AFP (>100 mg/dL) 51 (23%) 31 (41%)† 
     
 Events   
  Recurrence 151 (69%) NA 
  Death 139 (62%) 36 (43%)* 
     
 Median follow-up (months) 48.5 35 
     
* Cancer-related death in the validation set, as defined in Nault et al. Gastroenterology 
2013. † Missing values: bilirubin (n=32), AFP (n=7) 
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Table 2: Univariate and multivariate survival analyses of HCC patients (n=221) 
 
  Univariate analysis   Multivariate analysis (Cox Regression) 
Variable P-value   HR CI (95% low - high limits) P-value 
DNA methylation Mortality Index <0.001   13.35 7.94 - 22.42 <0.001 
Tumor size (>35 mm) <0.001         
Vascular invasion <0.001         
BCLC stage B or C <0.001         
Multinodularity <0.001   1.65 1.03 - 2.62 0.03 
Albumin levels (<3.5 gr/L) 0.001         
186-gene signature6 0.001         
Gender 0.005         
Platelet count (<100,000/mm3) 0.006   1.56 1.01 - 2.41 0.04 
AFP levels (>100 mg/dL) 0.02         
Bilirubin (>1 mg/dL) 0.02         
Satellites 0.03         
Etiology (HCV) 0.04         
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Table 3: Candidate tumor suppressors and oncogenes with aberrant methylation of promoters 
in hepatocellular carcinoma (Heptromic cohort, n=221).  
 
 Gene Chromosome location % hyper-methylated P value 






Genes reported aberrantly 




82 10 <0.001 
IGF2 11 51 100 0.001 
APC 5 78 0 <0.001 
NKX6-2 10 36 0 0.01 
SFRP5 10 7 0 ns 
NEFH 22 43 0 0.006 
RASSF5 1 6 0 ns 
Genes reported as drivers  
in other cancers  
 
NOTCH3 19 40 0 0.007 
NSD1 5 80 0 <0.001 
ZIC1 3 58 0 <0.001 
Candidate potential novel  
epidrivers in HCC  
 
 
SEPT9 17 61 0 
<0.001 
CDKL2 4 59 0 
<0.001 
DRD4 11 57 0 
<0.001 
FOXE3 1 57 0 
<0.001 
EFNB2 13 53 0 
<0.001 
TBX15 1 51 0 
0.001 
FAM196A 10 44 0 
0.005 
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Supplementary Table 1: Primers for pyrosequencing 
    Gene Sequence 
  CDKL2_FW_pyro GGTTTTTGYGTGTTAGGGAGTAGAAT  
  CDKL2_RV_pyro [Btn]CCAAACCTCCCTTCTTCTAAT  
  CDKL2_S GTGTTAGGGAGTAGAATT   
  DRD4_FW_pyro [Btn]AGGTTTTGTTAGATATTAGGTGGATTA  
  DRD4_RV_pyro AACCCAATATTTACTCATCTTAAAA  
  DRD4_S AACAAACCAACATC  
  FOXE3_FW_pyro ATAGTTTGGTGAATTTGTAGT 
  FOXE3_RV_pyro [Btn]AAACCCRACTACCTCAAATAAACCT   
  FOXE3_S AGTTTGGTGAATTTGT   
  EFNB2_FW_pyro GGGTGTTTTGATGGTTTTATGTAGAA 
  EFNB3_RV_pyro [Btn]AAAAATTCCAATAAATAAACTCTAAAACTA 
  EFNB4_S TGTTTTGATGGTTTTATGTAGA 
  C2Orf39_FW_pyro GTTGGYGGTAGGTTGGGTTTAG  
  C2Orf39_RV_pyro [Btn]CATAACAAAAATCCCTAATCCC  
  C2Orf39_S GTTTGTTTTTAGTAATTAGTTTGAG 
  CCNJ_FW_pyro TTAATTGGATTGGTTATTGTAGTGATTTAT  
  CCNJ_RV_pyro [Btn]ACTCCRCATACAAAACCAAC  
  CCNJ_S GATTTATTTTATAATTTT  
  KCNJ12_FW_pyro AGGGGTTYGGGGTTAGGT 
  KCNJ12_RV_pyro [Btn]AACTCAACTCRACAACTCCTCTAACTC 
  KCNJ12_S GTGGTAGGTTGGTGTA 
  SLC25A36_FW_pyro GATAGATATTAAGGGAATTGTTGGGTTATA 
  SLC25A36_RV_pyro [Btn]CCCRACATAAACAAAAACTCCCATT 
  SLC25A36_S GTTTATTTAGGTTAGGG 
  CLDN23_FW_pyro [Btn]AAGGAAGGTAGGTTGTAGG 
  CLDN23_RV_pyro ACTAACTAATTCAAAAAACCCTTCAC  
  CLDN23_S CAAAAAACCCTTCACC  
  NRCAM_FW_pyro [Btn]TGGAGTAGTTAGAGGGGATAG 
  NRCAM_RV_pyro CCCCCRAACAAAACCCAATATCAC  
  NRCAM_S ACTACCCAAAACCCTAA 
  EN2_FW_pyro AAGTGTTTGTAGGAGGAGTGT  
  EN2_RV_pyro [Btn]AAAAAAAAATAATATCACTCCCATTTAACT  
  EN2_S GTTTAAGATAGGAAGT 
  KCTD1_FW_pyro TGGGGGTTTTAGTGTGTAAT  
  KCTD1_RV_pyro [Btn]ACAAATTAAAACAAATCCCTACCT 
  KCTD1_S GTAGTGTATTGTGAAT 
  ZIC1_FW_pyro TGGTTTGTTAAAAGGGGATGTT 
  ZIC1_RV_pyro [Btn]ACCRTCCCCCCCTTAATAAATAAAAACA 
  ZIC1_S ATAATATTTGGGATTGATGAG 
  OLIG1_FW_pyro ATGTAGGATTTGAATTTGGTTATGG  
  OLIG1_RV_pyro [Btn]CCTACAACRAACTACCCAACAATAAAATAT  
  OLIG1_S GTAAGTTTTTTAAGATAGT  
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Supplementary Table 2: Methylation gene signature markers 
    
 
TargetID UCSC_REFGENE_NAME 
 1 cg00043788 VSX1 
 2 cg00586537 FAM65A 
 3 cg00696540 FYN 
 4 cg01227537 ZIC1 
 5 cg02318629 KCNK12 
 6 cg02571816 PPP1R14A 
 7 cg03578886 PDP1 
 8 cg03732762 OLIG1 
 9 cg03920233 DOC2A 
 10 cg04274978 CBLN3; KHNYN 
 11 cg04321866 EFNB2 
 12 cg04961553 OCIAD2 
 13 cg05412664 NRCAM 
 14 cg06521280 C10orf55; PLAU 
 15 cg06671706 CLDN23 
 16 cg07732116 DYNC1I1 
 17 cg08379212 CCNJ 
 18 cg09321747 SLC22A17 
 19 cg09472203 AP3B2 
 20 cg10481660 EN2 
 21 cg12881557 KCTD1 
 22 cg13414212 C2orf39 
 23 cg15019790 SIX2 
 24 cg15065139 GALNTL1 
 25 cg16113530 CCDC112 
 26 cg17157630 WDR54 
 27 cg17179589 LOC440461 
 28 cg18703913 LOC401097 
 29 cg21085535 FLYWCH2 
 30 cg22447539 FSCN1 
 31 cg22639895 KCNJ12 
 32 cg23083315 FJX1 
 33 cg23624808 ZNF397OS 
 34 cg23664775 SLC25A36 
 35 cg26527638 AZI1 
 36 cg26793648 PLEKHG4 
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Supplementary table 3: Gene sets enrichment analysis 
      
Gene sets enriched (FDR<0.25) in patients with high mortality index (>230) 
   




p-value FDR(<0.25) Database (http://www.broadinstitute.org/gsea/msigdb/) 
WNT_SIGNALING 89 1,52 0,010 0,010 SuperArray 
MOTOR_ACTIVITY 28 2,04 0,000 0,020 Gomf 
YAMASHITA_LIVER_CANCER_EPCAM 46 1,90 0,002 0,036 HCCsignatures 
ATP_DEPENDENT_RNA_HELICASE_ACTIVITY 16 1,90 0,004 0,040 Gomf 
ATP_DEPENDENT_HELICASE_ACTIVITY 26 1,96 0,000 0,043 Gomf 
HOSHIDA_S2 109 1,83 0,011 0,047 HCCsignatures 
TUBULIN_BINDING 47 1,91 0,002 0,047 Gomf 
DNA_POLYMERASE_ACTIVITY 18 1,87 0,000 0,048 Gomf 
HELICASE_ACTIVITY 49 1,85 0,000 0,048 Gomf 
CHROMATIN_BINDING 31 1,86 0,005 0,050 Gomf 
BOYAULT_LIVER_CANCER_SUBCLASS_G12 30 1,79 0,011 0,051 HCCsignatures 
RNA_DEPENDENT_ATPASE_ACTIVITY 17 1,81 0,015 0,051 Gomf 
SPINDLE 39 1,93 0,008 0,054 GOcc 
PROTEIN_C_TERMINUS_BINDING 71 1,83 0,000 0,054 Gomf 
MICROTUBULE_MOTOR_ACTIVITY 16 1,92 0,002 0,056 Gomf 
MICROTUBULE_ASSOCIATED_COMPLEX 47 1,88 0,002 0,056 GOcc 
RNA_HELICASE_ACTIVITY 23 1,81 0,004 0,056 Gomf 
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION 133 1,71 0,035 0,056 HCCsignatures 
SPINDLE_POLE 18 1,89 0,004 0,059 GOcc 
SPLICEOSOME 50 1,85 0,004 0,060 GOcc 
CHROMATIN 35 1,83 0,005 0,061 GOcc 
NUCLEAR_PORE 31 1,70 0,004 0,063 GOcc 
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CHROMOSOMAL_PART 96 1,78 0,014 0,065 GOcc 
NUCLEOLUS 124 1,77 0,009 0,065 GOcc 
CENTROSOME 55 1,69 0,018 0,065 GOcc 
ORGANELLE_LUMEN 452 1,70 0,000 0,066 GOcc 
CK19SIGNATURE_FDR010 149 1,66 0,049 0,066 HCCsignatures 
MICROTUBULE 32 1,80 0,004 0,067 GOcc 
BOYAULT_LIVER_CANCER_SUBCLASS_G3 132 1,71 0,030 0,067 HCCsignatures 
TRANSCRIPTION_FACTOR_COMPLEX 89 1,76 0,002 0,069 GOcc 
MEMBRANE_ENCLOSED_LUMEN 452 1,70 0,000 0,069 GOcc 
NUCLEAR_LUMEN 382 1,79 0,005 0,071 GOcc 
NUCLEAR_ENVELOPE 71 1,68 0,027 0,073 GOcc 
NUCLEOPLASM 275 1,70 0,009 0,073 GOcc 
CYTOSKELETAL_PART 228 1,67 0,007 0,074 GOcc 
MICROTUBULE_CYTOSKELETON 148 1,96 0,000 0,074 GOcc 
NUCLEOPLASM_PART 208 1,74 0,007 0,074 GOcc 
SPINDLE_MICROTUBULE 16 1,70 0,015 0,077 GOcc 
CHROMOSOME 123 1,72 0,029 0,080 GOcc 
RNA_BINDING 253 1,76 0,013 0,081 Gomf 
GOLGI_ASSOCIATED_VESICLE 29 1,70 0,013 0,081 GOcc 
LEE_LIVER_CANCER_POOR_SURVIVAL 122 1,62 0,043 0,082 HCCsignatures 
CCAGGTT,MIR-490 64 1,77 0,002 0,082 MIR 
MICROTUBULE_ORGANIZING_CENTER 64 1,72 0,002 0,082 GOcc 
PORE_COMPLEX 36 1,64 0,016 0,083 GOcc 
SMALL_NUCLEAR_RIBONUCLEOPROTEIN_COMPLEX 22 1,65 0,020 0,083 GOcc 
RIBONUCLEOPROTEIN_COMPLEX 142 1,71 0,011 0,084 GOcc 
MICROTUBULE_BINDING 33 1,74 0,009 0,085 Gomf 
NUCLEAR_MEMBRANE_PART 42 1,64 0,015 0,086 GOcc 
GTTAAAG,MIR-302B 68 1,73 0,005 0,093 MIR 
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SIG_INSULIN_RECEPTOR_PATHWAY_IN_CARDIAC_MYOCYTES 51 1,54 0,019 0,094 SignalGateway 
REACTOME_MITOTIC_G2_G2_M_PHASES 74 1,76 0,011 0,099 Reactome 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 43 1,68 0,017 0,101 Reactome 
REACTOME_GLOBAL_GENOMIC_NER_GG_NER 31 1,74 0,007 0,101 Reactome 
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX 30 1,74 0,027 0,101 Reactome 
REACTOME_SHC_MEDIATED_CASCADE 28 1,72 0,005 0,102 Reactome 
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_THE_CENTROMERE 55 1,68 0,030 0,102 Reactome 
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION 100 1,75 0,019 0,103 Reactome 
REACTOME_CELL_CYCLE_MITOTIC 303 1,74 0,020 0,103 Reactome 
REACTOME_RNA_POL_II_PRE_TRANSCRIPTION_EVENTS 57 1,69 0,017 0,103 Reactome 
REACTOME_ARMS_MEDIATED_ACTIVATION 17 1,68 0,022 0,103 Reactome 
REACTOME_DNA_STRAND_ELONGATION 30 1,72 0,030 0,103 Reactome 
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_REPLICATION 33 1,76 0,013 0,103 Reactome 
REACTOME_SIGNALLING_TO_P38_VIA_RIT_AND_RIN 15 1,69 0,022 0,103 Reactome 
REACTOME_HIV_LIFE_CYCLE 112 1,76 0,004 0,104 Reactome 
REACTOME_DEADENYLATION_OF_MRNA 19 1,69 0,009 0,104 Reactome 
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX 103 1,73 0,027 0,104 Reactome 
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 34 1,68 0,007 0,105 Reactome 
MYC_UP.V1_UP 174 1,53 0,044 0,105 C6 
REACTOME_SIGNALLING_TO_RAS 26 1,69 0,014 0,105 Reactome 
PRC2_EDD_UP.V1_UP 191 1,55 0,018 0,105 C6 
REACTOME_SIGNALLING_TO_ERKS 35 1,73 0,007 0,106 Reactome 
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY 44 1,70 0,004 0,106 Reactome 
REACTOME_PROTEIN_FOLDING 49 1,70 0,000 0,106 Reactome 
REACTOME_TRANSLATION 143 1,70 0,021 0,107 Reactome 
REACTOME_FRS2_MEDIATED_CASCADE 36 1,75 0,008 0,107 Reactome 
REACTOME_DIABETES_PATHWAYS 124 1,71 0,005 0,107 Reactome 
REACTOME_LAGGING_STRAND_SYNTHESIS 19 1,76 0,007 0,108 Reactome 
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REACTOME_RNA_POL_II_TRANSCRIPTION_PRE_INITIATION_AND_PROMOTER_OPENING 38 1,67 0,018 0,108 Reactome 
REACTOME_PROLONGED_ERK_ACTIVATION_EVENTS 19 1,67 0,018 0,109 Reactome 
REACTOME_METABOLISM_OF_NON_CODING_RNA 47 1,70 0,020 0,109 Reactome 
REACTOME_PEPTIDE_CHAIN_ELONGATION 84 1,71 0,030 0,109 Reactome 
ATPASE_ACTIVITY 110 1,71 0,009 0,109 Gomf 
REACTOME_NUCLEOTIDE_EXCISION_REPAIR 46 1,71 0,009 0,109 Reactome 
WANG_LIVER_CANCER_RECURRENCE 16 1,55 0,046 0,109 HCCsignatures 
REACTOME_TRANSCRIPTION 192 1,66 0,015 0,110 Reactome 
REACTOME_INFLUENZA_LIFE_CYCLE 134 1,77 0,013 0,110 Reactome 
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 103 1,66 0,041 0,110 Reactome 
REACTOME_TRANSPORT_OF_RIBONUCLEOPROTEINS_INTO_THE_HOST_NUCLEUS 27 1,66 0,026 0,112 Reactome 
REACTOME_NGF_SIGNALLING_VIA_TRKA_FROM_THE_PLASMA_MEMBRANE 132 1,65 0,005 0,112 Reactome 
DNA_HELICASE_ACTIVITY 24 1,69 0,011 0,113 Gomf 
PHOSPHATASE_REGULATOR_ACTIVITY 26 1,69 0,007 0,114 Gomf 
REACTOME_MITOTIC_M_M_G1_PHASES 168 1,77 0,015 0,115 Reactome 
CHROMATIN_REMODELING_COMPLEX 17 1,59 0,046 0,115 GOcc 
REACTOME_INSULIN_RECEPTOR_SIGNALLING_CASCADE 82 1,78 0,000 0,115 Reactome 
REACTOME_MRNA_SPLICING 107 1,64 0,048 0,116 Reactome 
REACTOME_SYNTHESIS_OF_DNA 90 1,64 0,027 0,116 Reactome 
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_MEMBRANE 107 1,77 0,012 0,116 Reactome 
TCTAGAG,MIR-517 46 1,80 0,000 0,116 MIR 
STRUCTURAL_CONSTITUENT_OF_RIBOSOME 79 1,68 0,022 0,117 Gomf 
REACTOME_TRANSCRIPTION_COUPLED_NER_TC_NER 41 1,64 0,031 0,117 Reactome 
REACTOME_PREFOLDIN_MEDIATED_TRANSFER_OF_SUBSTRATE_TO_CCT_TRIC 25 1,64 0,018 0,117 Reactome 
NUCLEAR_BODY 32 1,58 0,040 0,118 GOcc 
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_PROTEINS_AND_COMPLEXES 59 1,62 0,028 0,118 Reactome 
REACTOME_S_PHASE 106 1,63 0,029 0,119 Reactome 
REACTOME_RNA_POL_II_TRANSCRIPTION 100 1,61 0,020 0,119 Reactome 
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REACTOME_MRNA_PROCESSING 154 1,61 0,045 0,119 Reactome 
REACTOME_M_G1_TRANSITION 78 1,62 0,029 0,119 Reactome 
REACTOME_RESOLUTION_OF_AP_SITES_VIA_THE_MULTIPLE_NUCLEOTIDE_PATCH_REPLACEMENT_PATHWAY 17 1,63 0,042 0,119 Reactome 
REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 52 1,61 0,027 0,119 Reactome 
REACTOME_MRNA_SPLICING_MINOR_PATHWAY 42 1,62 0,028 0,119 Reactome 
REACTOME_APC_CDC20_MEDIATED_DEGRADATION_OF_NEK2A 21 1,63 0,030 0,119 Reactome 
INTERPHASE_OF_MITOTIC_CELL_CYCLE 61 1,72 0,017 0,119 Gobp 
REACTOME_L1CAM_INTERACTIONS 83 1,62 0,012 0,120 Reactome 
REACTOME_SIGNALING_BY_FGFR 108 1,61 0,008 0,120 Reactome 
REACTOME_BASE_EXCISION_REPAIR 19 1,61 0,045 0,120 Reactome 
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_ASSEMBLY 82 1,74 0,015 0,121 Gobp 
REACTOME_NEP_NS2_INTERACTS_WITH_THE_CELLULAR_EXPORT_MACHINERY 27 1,63 0,033 0,121 Reactome 
GACAGGG,MIR-339 66 1,67 0,002 0,121 MIR 
REACTOME_METABOLISM_OF_PROTEINS 415 1,78 0,004 0,122 Reactome 
WELCSH_BRCA1_TARGETS_DN 137 1,99 0,000 0,123 CGP 
CELL_CYCLE_PHASE 167 1,71 0,035 0,123 Gobp 
M_PHASE_OF_MITOTIC_CELL_CYCLE 85 1,73 0,022 0,123 Gobp 
MITOSIS 82 1,72 0,022 0,124 Gobp 
REACTOME_SHC_RELATED_EVENTS 15 1,88 0,002 0,124 Reactome 
REACTOME_DNA_REPLICATION 188 1,78 0,017 0,125 Reactome 
ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE 74 1,70 0,014 0,126 Gobp 
MRNA_PROCESSING_GO_0006397 70 1,74 0,015 0,127 Gobp 
ST_G_ALPHA_I_PATHWAY 35 1,60 0,011 0,127 SignalTransductionKE 
DNA_DEPENDENT_DNA_REPLICATION 54 1,69 0,032 0,127 Gobp 
TRANSCRIPTION_INITIATION_FROM_RNA_POLYMERASE_II_PROMOTER 29 1,70 0,015 0,129 Gobp 
MITOCHONDRIAL_OUTER_MEMBRANE 18 1,56 0,049 0,129 GOcc 
PROTEIN_N_TERMINUS_BINDING 36 1,66 0,008 0,130 Gomf 
NUCLEAR_MEMBRANE 50 1,56 0,031 0,130 GOcc 
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RNA_SPLICING 87 1,68 0,015 0,130 Gobp 
COATED_VESICLE 47 1,55 0,018 0,130 GOcc 
REACTOME_METABOLISM_OF_RNA 250 1,82 0,004 0,130 Reactome 
MICROTUBULE_BASED_PROCESS 80 1,68 0,007 0,131 Gobp 
REACTOME_POST_CHAPERONIN_TUBULIN_FOLDING_PATHWAY 16 1,59 0,035 0,131 Reactome 
BIOCARTA_INSULIN_PATHWAY 21 1,65 0,009 0,131 BIOCARTA 
NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_TRANSPORT 30 1,74 0,005 0,132 Gobp 
REACTOME_MITOTIC_PROMETAPHASE 86 1,78 0,019 0,132 Reactome 
REACTOME_SHC1_EVENTS_IN_EGFR_SIGNALING 15 1,59 0,032 0,132 Reactome 
REACTOME_METABOLISM_OF_MRNA 206 1,79 0,002 0,132 Reactome 
REACTOME_G1_S_TRANSITION 106 1,59 0,043 0,132 Reactome 
REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA 136 1,59 0,065 0,133 Reactome 
RPS14_DN.V1_DN 183 1,56 0,041 0,133 C6 
COATED_VESICLE_MEMBRANE 17 1,54 0,043 0,133 GOcc 
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_G2_M_TRANSITION 15 1,58 0,068 0,134 Reactome 
CONDENSED_CHROMOSOME 33 1,52 0,064 0,134 GOcc 
REACTOME_EXTENSION_OF_TELOMERES 27 1,89 0,002 0,135 Reactome 
MEMBRANE_COAT 17 1,52 0,058 0,135 GOcc 
PROTEASOME_COMPLEX 23 1,50 0,066 0,135 GOcc 
DNA_DIRECTED_RNA_POLYMERASEII_HOLOENZYME 66 1,50 0,025 0,135 GOcc 
RNA_EXPORT_FROM_NUCLEUS 19 1,67 0,018 0,136 Gobp 
PROTEIN_DNA_COMPLEX_ASSEMBLY 48 1,75 0,004 0,136 Gobp 
TRANSCRIPTION_INITIATION 35 1,75 0,011 0,136 Gobp 
RRNA_PROCESSING 15 1,66 0,022 0,137 Gobp 
INTERPHASE 67 1,66 0,026 0,137 Gobp 
ENDOMEMBRANE_SYSTEM 218 1,51 0,030 0,137 GOcc 
CSR_LATE_UP.V1_UP 168 1,67 0,010 0,137 C6 
REACTOME_LATE_PHASE_OF_HIV_LIFE_CYCLE 99 1,83 0,000 0,138 Reactome 
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MICROTUBULE_ORGANIZING_CENTER_PART 19 1,50 0,048 0,138 GOcc 
SIG_IL4RECEPTOR_IN_B_LYPHOCYTES 27 1,26 0,164 0,139 SignalGateway 
COATED_MEMBRANE 17 1,52 0,058 0,139 GOcc 
PERINUCLEAR_REGION_OF_CYTOPLASM 54 1,51 0,023 0,139 GOcc 
BIOCARTA_ERK_PATHWAY 28 1,86 0 0,140 BIOCARTA 
CELL_CYCLE_PROCESS 189 1,76 0,018 0,140 Gobp 
ORGANELLE_OUTER_MEMBRANE 24 1,49 0,058 0,140 GOcc 
REACTOME_NEGATIVE_REGULATION_OF_FGFR_SIGNALING 36 1,79 0,005 0,140 Reactome 
CHROMOSOMEPERICENTRIC_REGION 31 1,53 0,085 0,141 GOcc 
KINETOCHORE 25 1,52 0,069 0,141 GOcc 
M_PHASE 111 1,65 0,046 0,141 Gobp 
TCTGATA,MIR-361 87 1,64 0,005 0,141 MIR 
ER_GOLGI_INTERMEDIATE_COMPARTMENT 23 1,48 0,092 0,141 GOcc 
NUCLEAR_CHROMOSOME 54 1,48 0,059 0,142 GOcc 
REACTOME_CELL_CYCLE 387 1,80 0,013 0,142 Reactome 
CHROMATIN_REMODELING 25 1,64 0,031 0,143 Gobp 
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE 121 1,57 0,013 0,143 Reactome 
DNA_REPLICATION 98 1,78 0,002 0,143 Gobp 
REACTOME_UNFOLDED_PROTEIN_RESPONSE 75 1,81 0,009 0,143 Reactome 
PROTEIN_RNA_COMPLEX_ASSEMBLY 63 1,63 0,040 0,143 Gobp 
BIOCARTA_MCM_PATHWAY 18 1,66 0,028 0,144 BIOCARTA 
REACTOME_DARPP_32_EVENTS 24 1,57 0,017 0,145 Reactome 
REACTOME_ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDING_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDI
NG_TO_43S 54 1,56 0,078 0,145 Reactome 
RAS_GTPASE_BINDING 25 1,60 0,022 0,146 Gomf 
BIOCARTA_WNT_PATHWAY 26 1,70 0,000 0,146 BIOCARTA 
RRNA_METABOLIC_PROCESS 16 1,64 0,033 0,147 Gobp 
REACTOME_ELONGATION_ARREST_AND_RECOVERY 31 1,56 0,045 0,147 Reactome 
REGULATION_OF_TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER 287 1,64 0,005 0,148 Gobp 
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CHROMATIN_MODIFICATION 52 1,62 0,021 0,149 Gobp 
TCCAGAG,MIR-518C 143 1,58 0,008 0,149 MIR 
TRANSCRIPTION_COREPRESSOR_ACTIVITY 91 1,60 0,000 0,150 Gomf 
CELL_CYCLE_GO_0007049 311 1,76 0,007 0,150 Gobp 
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE 76 1,54 0,071 0,151 Reactome 
REACTOME_CELL_CYCLE_CHECKPOINTS 111 1,53 0,076 0,151 Reactome 
ATPASE_ACTIVITY_COUPLED 91 1,62 0,007 0,151 Gomf 
REACTOME_GOLGI_ASSOCIATED_VESICLE_BIOGENESIS 51 1,54 0,051 0,152 Reactome 
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_THE_43S_COMPLEX 46 1,54 0,089 0,152 Reactome 
REACTOME_HIV_INFECTION 191 1,54 0,045 0,152 Reactome 
REACTOME_SIGNALING_BY_EGFR_IN_CANCER 105 1,54 0,016 0,153 Reactome 
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_STRAND 15 1,85 0,000 0,154 Reactome 
ORGANELLE_ENVELOPE 164 1,46 0,085 0,154 GOcc 
REACTOME_FORMATION_OF_RNA_POL_II_ELONGATION_COMPLEX_ 41 1,55 0,039 0,154 Reactome 
DNA_DEPENDENT_ATPASE_ACTIVITY 21 1,62 0,035 0,154 Gomf 
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS 35 1,54 0,097 0,154 Reactome 
DNA_PACKAGING 34 1,88 0,002 0,154 Gobp 
GTAGGCA,MIR-189 27 1,61 0,015 0,155 MIR 
RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY 180 1,61 0,010 0,155 Gomf 
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_CYCLIN_B 19 1,54 0,054 0,155 Reactome 
EARLY_ENDOSOME 18 1,45 0,084 0,155 GOcc 
REACTOME_DNA_REPAIR 102 1,55 0,029 0,155 Reactome 
REACTOME_FANCONI_ANEMIA_PATHWAY 21 1,83 0,000 0,155 Reactome 
UNFOLDED_PROTEIN_BINDING 42 1,60 0,035 0,155 Gomf 
REACTOME_PI3K_CASCADE 67 1,53 0,007 0,155 Reactome 
CHROMOSOME_ORGANIZATION_AND_BIOGENESIS 121 1,61 0,026 0,155 Gobp 
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING 35 1,63 0,028 0,155 Gomf 
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION 17 1,52 0,096 0,156 Reactome 
















This article is protected by copyright. All rights reserved.
NUCLEAR_TRANSPORT 85 1,60 0,009 0,156 Gobp 
TRANSLATION 175 1,61 0,041 0,156 Gobp 
CHROMATIN_ASSEMBLY 16 1,78 0,002 0,156 Gobp 
REACTOME_ORC1_REMOVAL_FROM_CHROMATIN 65 1,52 0,077 0,156 Reactome 
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX 63 1,52 0,077 0,156 Reactome 
REACTOME_G2_M_CHECKPOINTS 41 1,55 0,082 0,156 Reactome 
REACTOME_SIGNALING_BY_INSULIN_RECEPTOR 103 1,53 0,014 0,156 Reactome 
REACTOME_FORMATION_OF_THE_HIV1_EARLY_ELONGATION_COMPLEX 31 1,52 0,062 0,157 Reactome 
REACTOME_EGFR_DOWNREGULATION 24 1,52 0,047 0,157 Reactome 
ENVELOPE 164 1,46 0,085 0,157 GOcc 
ST_G_ALPHA_S_PATHWAY 16 1,41 0,073 0,158 SignalTransductionKE 
BIOCARTA_G1_PATHWAY 28 1,67 0,019 0,159 BIOCARTA 
VESICLE_COAT 16 1,45 0,101 0,159 GOcc 
CTACCTC,LET-7A,LET-7B,LET-7C,LET-7D,LET-7E,LET-7F,MIR-98,LET-7G,LET-7I 384 1,59 0,003 0,160 MIR 
NUCLEOCYTOPLASMIC_TRANSPORT 84 1,59 0,012 0,161 Gobp 
TANG_SENESCENCE_TP53_TARGETS_DN 56 1,76 0,018 0,161 CGP 
BIOCARTA_PITX2_PATHWAY 15 1,71 0,014 0,162 BIOCARTA 
NUCLEOTIDYLTRANSFERASE_ACTIVITY 47 1,57 0,039 0,162 Gomf 
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_TRIC 19 1,51 0,074 0,163 Reactome 
MAYBURD_RESPONSE_TO_L663536_UP 26 1,75 0,004 0,164 CGP 
CROONQUIST_IL6_DEPRIVATION_DN 96 1,75 0,027 0,164 CGP 
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_DN 28 1,72 0,012 0,165 CGP 
FOURNIER_ACINAR_DEVELOPMENT_LATE_2 273 1,72 0,020 0,165 CGP 
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP 146 1,76 0,030 0,165 CGP 
WHITFIELD_CELL_CYCLE_G2 171 1,63 0,030 0,165 CGP 
KOBAYASHI_EGFR_SIGNALING_24HR_DN 246 1,72 0,030 0,166 CGP 
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR 17 1,50 0,045 0,166 Reactome 
SIG_PIP3_SIGNALING_IN_CARDIAC_MYOCTES 67 1,28 0,094 0,166 SignalGateway 
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WHITFIELD_CELL_CYCLE_M_G1 136 1,62 0,005 0,166 CGP 
LEONARD_HYPOXIA 46 1,61 0,044 0,166 CGP 
BENPORATH_PROLIFERATION 143 1,63 0,060 0,166 CGP 
TRANSCRIPTION_FACTOR_BINDING 300 1,52 0,010 0,167 Gomf 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 447 1,75 0,024 0,167 CGP 
NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON 31 1,63 0,028 0,167 CGP 
HORIUCHI_WTAP_TARGETS_DN 302 1,75 0,023 0,167 CGP 
WU_APOPTOSIS_BY_CDKN1A_VIA_TP53 53 1,62 0,091 0,167 CGP 
HOLLEMAN_ASPARAGINASE_RESISTANCE_B_ALL_UP 26 1,61 0,046 0,167 CGP 
FUJII_YBX1_TARGETS_DN 199 1,73 0,023 0,167 CGP 
KORKOLA_CORRELATED_WITH_POU5F1 31 1,63 0,024 0,167 CGP 
AMIT_SERUM_RESPONSE_480_MCF10A 37 1,64 0,009 0,168 CGP 
NAGY_TFTC_COMPONENTS_HUMAN 19 1,63 0,015 0,168 CGP 
ACTIN_FILAMENT_BINDING 25 1,57 0,027 0,168 Gomf 
THYROID_HORMONE_RECEPTOR_BINDING 17 1,56 0,039 0,168 Gomf 
AMUNDSON_GAMMA_RADIATION_RESPONSE 39 1,76 0,024 0,168 CGP 
FARMER_BREAST_CANCER_CLUSTER_2 32 1,62 0,041 0,168 CGP 
REACTOME_MITOTIC_G1_G1_S_PHASES 130 1,50 0,078 0,168 Reactome 
REACTOME_MEMBRANE_TRAFFICKING 125 1,50 0,041 0,168 Reactome 
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_UP 47 1,63 0,014 0,169 CGP 
LY_AGING_OLD_DN 55 1,63 0,033 0,169 CGP 
ROY_WOUND_BLOOD_VESSEL_DN 22 1,64 0,028 0,169 CGP 
WINNEPENNINCKX_MELANOMA_METASTASIS_UP 157 1,63 0,052 0,169 CGP 
WINTER_HYPOXIA_UP 86 1,62 0,021 0,169 CGP 
WEST_ADRENOCORTICAL_TUMOR_MARKERS_UP 21 1,62 0,043 0,170 CGP 
BROWNE_HCMV_INFECTION_2HR_DN 48 1,73 0,010 0,170 CGP 
LI_AMPLIFIED_IN_LUNG_CANCER 175 1,64 0,031 0,170 CGP 
TIEN_INTESTINE_PROBIOTICS_6HR_UP 55 1,63 0,043 0,170 CGP 
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SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC 107 1,62 0,024 0,170 CGP 
CACGTTT,MIR-302A 30 1,55 0,025 0,171 MIR 
RIBOSOME 39 1,43 0,121 0,171 GOcc 
REACTOME_DOWNSTREAM_SIGNALING_OF_ACTIVATED_FGFR 97 1,49 0,023 0,171 Reactome 
REACTOME_CHROMOSOME_MAINTENANCE 111 1,93 0,002 0,171 Reactome 
TRANSLATION_INITIATION_FACTOR_ACTIVITY 23 1,52 0,063 0,171 Gomf 
VESICLE_MEMBRANE 30 1,42 0,086 0,171 GOcc 
STRUCTURAL_MOLECULE_ACTIVITY 237 1,54 0,067 0,171 Gomf 
LIN_MELANOMA_COPY_NUMBER_UP 69 1,62 0,018 0,171 CGP 
NUCLEAR_CHROMOSOME_PART 34 1,42 0,084 0,171 GOcc 
LY_AGING_MIDDLE_DN 16 1,64 0,026 0,171 CGP 
G1_PHASE 15 1,78 0,009 0,171 Gobp 
LEE_LIVER_CANCER_SURVIVAL_DN 169 1,73 0,020 0,172 CGP 
KUUSELO_PANCREATIC_CANCER_19Q13_AMPLIFICATION 31 1,62 0,030 0,172 CGP 
REACTOME_KINESINS 23 1,90 0,002 0,172 Reactome 
NAGY_STAGA_COMPONENTS_HUMAN 15 1,61 0,026 0,172 CGP 
VECCHI_GASTRIC_CANCER_EARLY_UP 406 1,76 0,019 0,172 CGP 
REACTOME_SHC1_EVENTS_IN_ERBB4_SIGNALING 20 1,49 0,053 0,172 Reactome 
BIOCARTA_CARM_ER_PATHWAY 34 1,57 0,024 0,172 BIOCARTA 
CYTOSKELETON_DEPENDENT_INTRACELLULAR_TRANSPORT 26 1,58 0,020 0,172 Gobp 
MISSIAGLIA_REGULATED_BY_METHYLATION_DN 117 1,73 0,038 0,173 CGP 
CAMPS_COLON_CANCER_COPY_NUMBER_UP 86 1,64 0,007 0,173 CGP 
NUCLEAR_HORMONE_RECEPTOR_BINDING 28 1,55 0,040 0,173 Gomf 
BIOCARTA_UCALPAIN_PATHWAY 18 1,60 0,038 0,173 BIOCARTA 
OXFORD_RALA_OR_RALB_TARGETS_UP 48 1,64 0,046 0,173 CGP 
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP 49 1,61 0,018 0,173 CGP 
SONG_TARGETS_OF_IE86_CMV_PROTEIN 59 1,60 0,065 0,173 CGP 
REACTOME_INTERACTIONS_OF_VPR_WITH_HOST_CELLULAR_PROTEINS 32 1,49 0,053 0,174 Reactome 
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PROTEIN_SERINE_THREONINE_PHOSPHATASE_ACTIVITY 24 1,52 0,058 0,174 Gomf 
IIZUKA_LIVER_CANCER_PROGRESSION_G1_G2_DN 25 1,64 0,028 0,174 CGP 
BIOCARTA_IGF1R_PATHWAY 23 1,53 0,038 0,174 BIOCARTA 
ZHAN_MULTIPLE_MYELOMA_PR_UP 42 1,73 0,017 0,174 CGP 
KAUFFMANN_MELANOMA_RELAPSE_UP 58 1,64 0,048 0,175 CGP 
BLUM_RESPONSE_TO_SALIRASIB_DN 332 1,65 0,048 0,175 CGP 
FERREIRA_EWINGS_SARCOMA_UNSTABLE_VS_STABLE_UP 162 1,60 0,050 0,175 CGP 
BIOCARTA_IGF1_PATHWAY 21 1,59 0,019 0,175 BIOCARTA 
SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 32 1,65 0,027 0,175 CGP 
FOURNIER_ACINAR_DEVELOPMENT_LATE_DN 21 1,65 0,016 0,175 CGP 
REACTOME_INHIBITION_OF_THE_PROTEOLYTIC_ACTIVITY_OF_APC_C_REQUIRED_FOR_THE_ONSET_OF_ANAPHASE_BY_MITOTIC_SPI
NDLE_CHECKPOINT_COMPONENTS 18 1,48 0,083 0,175 Reactome 
SCIBETTA_KDM5B_TARGETS_DN 78 1,60 0,031 0,175 CGP 
HEIDENBLAD_AMPLICON_8Q24_UP 37 2,00 0,000 0,175 CGP 
LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_UP 169 1,64 0,025 0,176 CGP 
EGUCHI_CELL_CYCLE_RB1_TARGETS 23 1,64 0,037 0,176 CGP 
TRANSLATION_REGULATOR_ACTIVITY 37 1,54 0,048 0,176 Gomf 
NUCLEOSIDE_TRIPHOSPHATASE_ACTIVITY 204 1,53 0,009 0,176 Gomf 
PURBEY_TARGETS_OF_CTBP1_AND_SATB1_DN 175 1,60 0,003 0,176 CGP 
PYROPHOSPHATASE_ACTIVITY 218 1,51 0,016 0,176 Gomf 
HORMONE_RECEPTOR_BINDING 29 1,53 0,049 0,176 Gomf 
MUELLER_PLURINET 288 1,64 0,021 0,176 CGP 
RIBOSOME_BIOGENESIS_AND_ASSEMBLY 18 1,57 0,063 0,176 Gobp 
CHENG_IMPRINTED_BY_ESTRADIOL 102 1,60 0,005 0,176 CGP 
NUTT_GBM_VS_AO_GLIOMA_DN 45 1,64 0,021 0,176 CGP 
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_UP 39 1,60 0,007 0,176 CGP 
DANG_MYC_TARGETS_UP 138 1,71 0,014 0,176 CGP 
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN 22 1,73 0,015 0,176 CGP 
BENPORATH_ES_2 39 1,74 0,008 0,176 CGP 
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REPLICATION_FORK 18 1,41 0,109 0,177 GOcc 
BACOLOD_RESISTANCE_TO_ALKYLATING_AGENTS_DN 60 1,60 0,010 0,177 CGP 
PENG_RAPAMYCIN_RESPONSE_DN 241 1,65 0,017 0,177 CGP 
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP 185 1,76 0,024 0,177 CGP 
AATGGAG,MIR-136 76 1,50 0,025 0,178 MIR 
ROSTY_CERVICAL_CANCER_PROLIFERATION_CLUSTER 138 1,71 0,041 0,178 CGP 
WHITEFORD_PEDIATRIC_CANCER_MARKERS 112 1,65 0,044 0,179 CGP 
VANTVEER_BREAST_CANCER_METASTASIS_DN 117 1,59 0,045 0,179 CGP 
DAIRKEE_CANCER_PRONE_RESPONSE_BPA 51 1,59 0,017 0,179 CGP 
ODONNELL_TFRC_TARGETS_DN 130 1,59 0,091 0,179 CGP 
MOHANKUMAR_TLX1_TARGETS_UP 400 1,59 0,012 0,180 CGP 
CHANG_CYCLING_GENES 143 1,77 0,029 0,180 CGP 
TIEN_INTESTINE_PROBIOTICS_24HR_DN 207 1,76 0,005 0,180 CGP 
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_DN 87 1,59 0,073 0,180 CGP 
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN 57 1,73 0,029 0,180 CGP 
CHEN_HOXA5_TARGETS_9HR_DN 40 1,65 0,030 0,181 CGP 
WONG_EMBRYONIC_STEM_CELL_CORE 330 1,65 0,037 0,181 CGP 
REACTOME_TRANS_GOLGI_NETWORK_VESICLE_BUDDING 58 1,48 0,069 0,181 Reactome 
DELPUECH_FOXO3_TARGETS_DN 39 1,69 0,019 0,181 CGP 
KAUFFMANN_DNA_REPLICATION_GENES 142 1,66 0,043 0,181 CGP 
DAZARD_UV_RESPONSE_CLUSTER_G4 18 1,58 0,023 0,181 CGP 
NUCLEOLAR_PART 18 1,40 0,125 0,181 GOcc 
LEE_EARLY_T_LYMPHOCYTE_UP 100 1,66 0,064 0,181 CGP 
BIOCARTA_HER2_PATHWAY 22 1,54 0,026 0,181 BIOCARTA 
GRADE_COLON_AND_RECTAL_CANCER_UP 280 1,70 0,011 0,181 CGP 
FLOTHO_PEDIATRIC_ALL_THERAPY_RESPONSE_UP 53 1,58 0,057 0,182 CGP 
HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2 18 1,58 0,057 0,182 CGP 
PUJANA_BRCA2_PCC_NETWORK 414 1,58 0,041 0,182 CGP 
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MARIADASON_RESPONSE_TO_CURCUMIN_SULINDAC_7 18 1,69 0,014 0,182 CGP 
REACTOME_APC_C_CDH1_MEDIATED_DEGRADATION_OF_CDC20_AND_OTHER_APC_C_CDH1_TARGETED_PROTEINS_IN_LATE_MITO
SIS_EARLY_G1 63 1,48 0,097 0,182 Reactome 
MENSSEN_MYC_TARGETS 52 1,58 0,043 0,182 CGP 
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_DN 47 1,66 0,025 0,182 CGP 
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_UP 59 1,58 0,005 0,182 CGP 
AIYAR_COBRA1_TARGETS_DN 29 1,58 0,024 0,182 CGP 
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_UP 177 1,65 0,052 0,183 CGP 
WHITFIELD_CELL_CYCLE_G2_M 213 1,58 0,025 0,183 CGP 
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION 24 1,48 0,076 0,183 Reactome 
REN_BOUND_BY_E2F 59 1,58 0,071 0,183 CGP 
HEDENFALK_BREAST_CANCER_BRACX_UP 20 1,57 0,048 0,184 CGP 
LOPEZ_MESOTHELIOMA_SURVIVAL_OVERALL_DN 15 1,67 0,005 0,184 CGP 
SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP 468 1,57 0,011 0,184 CGP 
REACTOME_SYNTHESIS_OF_GLYCOSYLPHOSPHATIDYLINOSITOL_GPI 17 1,47 0,088 0,184 Reactome 
BOYAULT_LIVER_CANCER_SUBCLASS_G12_UP 37 1,70 0,036 0,185 CGP 
PUJANA_BRCA_CENTERED_NETWORK 116 1,66 0,041 0,185 CGP 
HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES 220 1,50 0,018 0,185 Gomf 
THILLAINADESAN_ZNF217_TARGETS_UP 42 1,69 0,018 0,185 CGP 
BASAKI_YBX1_TARGETS_UP 277 1,67 0,027 0,185 CGP 
GAJATE_RESPONSE_TO_TRABECTEDIN_DN 18 1,77 0,002 0,185 CGP 
CHNG_MULTIPLE_MYELOMA_HYPERPLOID_UP 51 1,66 0,050 0,186 CGP 
MACLACHLAN_BRCA1_TARGETS_UP 21 1,68 0,007 0,186 CGP 
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP 21 1,70 0,014 0,186 CGP 
ATAGGAA,MIR-202 100 1,44 0,063 0,186 MIR 
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_DN 51 1,66 0,007 0,186 CGP 
CTGTTAC,MIR-194 105 1,43 0,060 0,187 MIR 
CTCTGGA,MIR-520A,MIR-525 153 1,48 0,026 0,187 MIR 
PENG_LEUCINE_DEPRIVATION_DN 183 1,70 0,009 0,187 CGP 
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KANG_DOXORUBICIN_RESISTANCE_UP 53 1,67 0,037 0,187 CGP 
RAMASWAMY_METASTASIS_UP 64 1,80 0,002 0,188 CGP 
REACTOME_REGULATION_OF_GLUCOKINASE_BY_GLUCOKINASE_REGULATORY_PROTEIN 27 1,46 0,073 0,188 Reactome 
BIOCARTA_CK1_PATHWAY 17 1,57 0,037 0,188 BIOCARTA 
WEST_ADRENOCORTICAL_TUMOR_UP 286 1,66 0,021 0,188 CGP 
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 116 1,66 0,009 0,188 CGP 
SARRIO_EPITHELIAL_MESENCHYMAL_TRANSITION_UP 172 1,68 0,030 0,188 CGP 
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP 29 1,68 0,021 0,189 CGP 
REACTOME_ABORTIVE_ELONGATION_OF_HIV1_TRANSCRIPT_IN_THE_ABSENCE_OF_TAT 23 1,46 0,085 0,189 Reactome 
RHODES_CANCER_META_SIGNATURE 62 1,56 0,045 0,189 CGP 
APPIERTO_RESPONSE_TO_FENRETINIDE_UP 38 1,57 0,024 0,189 CGP 
SILIGAN_TARGETS_OF_EWS_FLI1_FUSION_DN 18 1,67 0,016 0,189 CGP 
TCATCTC,MIR-143 145 1,44 0,010 0,190 MIR 
CHEMNITZ_RESPONSE_TO_PROSTAGLANDIN_E2_UP 142 1,80 0,014 0,190 CGP 
HOSHIDA_LIVER_CANCER_SUBCLASS_S2 113 1,80 0,015 0,190 CGP 
BORCZUK_MALIGNANT_MESOTHELIOMA_UP 296 1,57 0,052 0,190 CGP 
DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP 315 1,77 0,037 0,190 CGP 
SMID_BREAST_CANCER_LUMINAL_A_DN 17 1,56 0,074 0,190 CGP 
REACTOME_ENDOSOMAL_SORTING_COMPLEX_REQUIRED_FOR_TRANSPORT_ESCRT 25 1,46 0,076 0,190 Reactome 
REACTOME_BASIGIN_INTERACTIONS 24 1,45 0,059 0,190 Reactome 
SHIPP_DLBCL_CURED_VS_FATAL_DN 45 1,56 0,029 0,190 CGP 
BENPORATH_MYC_TARGETS_WITH_EBOX 219 1,56 0,012 0,191 CGP 
REACTOME_DESTABILIZATION_OF_MRNA_BY_TRISTETRAPROLIN_TTP 17 1,46 0,067 0,191 Reactome 
ABRAMSON_INTERACT_WITH_AIRE 45 1,84 0,009 0,191 CGP 
AGTCTAG,MIR-151 24 1,50 0,039 0,191 MIR 
REACTOME_ACTIVATION_OF_GENES_BY_ATF4 24 1,45 0,075 0,192 Reactome 
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP 172 1,67 0,044 0,192 CGP 
REACTOME_SIGNALLING_BY_NGF 210 1,46 0,022 0,192 Reactome 
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TCCCCAC,MIR-491 56 1,48 0,053 0,193 MIR 
HOXA9_DN.V1_DN 185 1,56 0,008 0,193 C6 
MRNA_METABOLIC_PROCESS 81 1,78 0,013 0,193 Gobp 
CONDENSED_NUCLEAR_CHROMOSOME 18 1,38 0,122 0,193 GOcc 
CAATGCA,MIR-33 91 1,44 0,025 0,193 MIR 
BROWNE_HCMV_INFECTION_18HR_UP 172 1,67 0,000 0,193 CGP 
BIOCARTA_SPRY_PATHWAY 18 1,54 0,043 0,195 BIOCARTA 
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON 319 1,55 0,080 0,196 CGP 
LEE_METASTASIS_AND_RNA_PROCESSING_UP 17 1,55 0,048 0,196 CGP 
FURUKAWA_DUSP6_TARGETS_PCI35_DN 71 1,67 0,032 0,196 CGP 
PUJANA_BREAST_CANCER_LIT_INT_NETWORK 100 1,67 0,019 0,196 CGP 
NEGATIVE_REGULATION_OF_DNA_METABOLIC_PROCESS 18 1,56 0,037 0,196 Gobp 
RNA_POLYMERASE_ACTIVITY 16 1,48 0,095 0,196 Gomf 
MITSIADES_RESPONSE_TO_APLIDIN_DN 244 1,77 0,016 0,196 CGP 
CROONQUIST_NRAS_VS_STROMAL_STIMULATION_DN 97 1,55 0,050 0,197 CGP 
MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_6 48 1,55 0,015 0,197 CGP 
ACTGCAG,MIR-17-3P 109 1,45 0,037 0,197 MIR 
MANALO_HYPOXIA_DN 282 1,77 0,020 0,197 CGP 
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_DN 64 1,55 0,033 0,198 CGP 
SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 46 1,79 0,000 0,198 CGP 
NADERI_BREAST_CANCER_PROGNOSIS_UP 48 1,67 0,038 0,198 CGP 
DANG_REGULATED_BY_MYC_UP 70 1,55 0,038 0,199 CGP 
BHATTACHARYA_EMBRYONIC_STEM_CELL 85 1,80 0,010 0,199 CGP 
KYNG_NORMAL_AGING_UP 17 1,55 0,040 0,199 CGP 
ST_WNT_BETA_CATENIN_PATHWAY 33 1,44 0,050 0,199 SignalTransductionKE 
NEGATIVE_REGULATION_OF_RNA_METABOLIC_PROCESS 131 1,55 0,013 0,200 Gobp 
UBIQUITIN_LIGASE_COMPLEX 26 1,37 0,104 0,200 GOcc 
LI_WILMS_TUMOR_ANAPLASTIC_UP 18 1,67 0,032 0,200 CGP 
















This article is protected by copyright. All rights reserved.
NEGATIVE_REGULATION_OF_NUCLEOBASENUCLEOSIDENUCLEOTIDE_AND_NUCLEIC_ACID_METABOLIC_PROCESS 206 1,54 0,008 0,200 Gobp 
ZHANG_RESPONSE_TO_CANTHARIDIN_DN 67 1,55 0,064 0,201 CGP 
REACTOME_MEIOTIC_SYNAPSIS 66 1,44 0,102 0,201 Reactome 
CYTOSKELETON 358 1,37 0,034 0,201 GOcc 
TRANSCRIPTION_FROM_RNA_POLYMERASE_II_PROMOTER 453 1,55 0,005 0,201 Gobp 
MITOTIC_CELL_CYCLE 152 1,81 0,012 0,202 Gobp 
REGULATION_OF_TRANSCRIPTIONDNA_DEPENDENT 457 1,53 0,011 0,202 Gobp 
GARCIA_TARGETS_OF_FLI1_AND_DAX1_DN 169 1,85 0,002 0,202 CGP 
MACROMOLECULE_BIOSYNTHETIC_PROCESS 316 1,53 0,027 0,202 Gobp 
SMALL_GTPASE_BINDING 33 1,47 0,038 0,203 Gomf 
LINSLEY_MIR16_TARGETS 202 1,78 0,000 0,203 CGP 
TRANSCRIPTION_COFACTOR_ACTIVITY 224 1,47 0,016 0,203 Gomf 
CHANDRAN_METASTASIS_UP 204 1,54 0,005 0,203 CGP 
GAGACTG,MIR-452 92 1,44 0,028 0,203 MIR 
HEDENFALK_BREAST_CANCER_HEREDITARY_VS_SPORADIC 49 1,54 0,028 0,203 CGP 
ORGANELLE_MEMBRANE 297 1,36 0,101 0,203 GOcc 
CYTOPLASMIC_VESICLE_PART 28 1,36 0,125 0,203 GOcc 
TIEN_INTESTINE_PROBIOTICS_2HR_UP 27 1,54 0,049 0,203 CGP 
REACTOME_PI3K_AKT_ACTIVATION 36 1,44 0,061 0,203 Reactome 
KEGG_NUCLEOTIDE_EXCISION_REPAIR 42 1,75 0,000 0,203 KEGG 
TOYOTA_TARGETS_OF_MIR34B_AND_MIR34C 429 1,78 0,007 0,204 CGP 
NEGATIVE_REGULATION_OF_TRANSCRIPTION_DNA_DEPENDENT 129 1,54 0,013 0,204 Gobp 
REGULATION_OF_MITOTIC_CELL_CYCLE 23 1,52 0,049 0,205 Gobp 
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_UP 22 1,77 0,005 0,205 CGP 
GAGCTGG,MIR-337 156 1,50 0,032 0,205 MIR 
REACTOME_POST_TRANSLATIONAL_MODIFICATION_SYNTHESIS_OF_GPI_ANCHORED_PROTEINS 26 1,43 0,101 0,205 Reactome 
REGULATION_OF_RNA_METABOLIC_PROCESS 466 1,53 0,011 0,205 Gobp 
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR 85 1,82 0,021 0,206 CGP 
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ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR 125 1,85 0,018 0,206 CGP 
CYTOPLASMIC_VESICLE_MEMBRANE 28 1,36 0,125 0,207 GOcc 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION 120 1,43 0,039 0,208 Reactome 
MICROTUBULE_BASED_MOVEMENT 16 1,52 0,045 0,208 Gobp 
CAGCCTC,MIR-485-5P 139 1,45 0,032 0,208 MIR 
VEGF_A_UP.V1_DN 191 1,39 0,059 0,208 C6 
REACTOME_PIP3_ACTIVATES_AKT_SIGNALING 27 1,43 0,082 0,208 Reactome 
RHODES_UNDIFFERENTIATED_CANCER 66 1,54 0,084 0,208 CGP 
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN 43 1,81 0,011 0,208 CGP 
BROWNE_HCMV_INFECTION_24HR_UP 146 1,54 0,003 0,209 CGP 
OZEN_MIR125B1_TARGETS 25 1,53 0,017 0,209 CGP 
BENPORATH_ES_1 369 1,53 0,031 0,209 CGP 
BONOME_OVARIAN_CANCER_POOR_SURVIVAL_DN 22 1,83 0,002 0,209 CGP 
GLYCOLIPID_METABOLIC_PROCESS 16 1,52 0,043 0,209 Gobp 
ORGANELLE_ORGANIZATION_AND_BIOGENESIS 464 1,50 0,008 0,209 Gobp 
MATTIOLI_MGUS_VS_MULTIPLE_MYELOMA 16 1,80 0,002 0,210 CGP 
REACTOME_MEIOSIS 102 1,43 0,115 0,210 Reactome 
MICROTUBULE_ORGANIZING_CENTER_ORGANIZATION_AND_BIOGENESIS 15 1,49 0,075 0,210 Gobp 
REACTOME_RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION 106 1,42 0,096 0,210 Reactome 
ATGCACG,MIR-517B 18 1,46 0,048 0,211 MIR 
FAELT_B_CLL_WITH_VH3_21_UP 43 1,53 0,040 0,211 CGP 
TRANSLATIONAL_INITIATION 37 1,49 0,087 0,211 Gobp 
DACOSTA_UV_RESPONSE_VIA_ERCC3_TTD_UP 63 1,53 0,029 0,211 CGP 
BIOCARTA_NGF_PATHWAY 18 1,49 0,057 0,212 BIOCARTA 
ESTABLISHMENT_OF_CELLULAR_LOCALIZATION 346 1,49 0,009 0,212 Gobp 
XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_DN 20 1,53 0,058 0,212 CGP 
DNA_METABOLIC_PROCESS 247 1,51 0,032 0,212 Gobp 
PATTERN_SPECIFICATION_PROCESS 30 1,48 0,031 0,212 Gobp 
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SYNAPSE_ORGANIZATION_AND_BIOGENESIS 23 1,50 0,088 0,212 Gobp 
RNA_SPLICINGVIA_TRANSESTERIFICATION_REACTIONS 32 1,48 0,073 0,212 Gobp 
PROTEIN_TARGETING 106 1,50 0,010 0,213 Gobp 
GTPASE_BINDING 34 1,46 0,040 0,214 Gomf 
REGULATION_OF_CELL_CYCLE 182 1,48 0,022 0,214 Gobp 
INTRACELLULAR_TRANSPORT 275 1,51 0,015 0,214 Gobp 
BIOCARTA_ARAP_PATHWAY 17 1,71 0,012 0,214 BIOCARTA 
CCTGAGT,MIR-510 41 1,40 0,046 0,214 MIR 
CCTGCTG,MIR-214 231 1,51 0,005 0,215 MIR 
BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP 44 1,88 0,009 0,215 CGP 
BIOCARTA_CCR3_PATHWAY 23 1,48 0,055 0,215 BIOCARTA 
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN 22 1,53 0,061 0,216 CGP 
GENTILE_UV_RESPONSE_CLUSTER_D5 39 1,52 0,036 0,216 CGP 
NEGATIVE_REGULATION_OF_TRANSCRIPTION 183 1,48 0,013 0,217 Gobp 
CROONQUIST_NRAS_SIGNALING_DN 71 1,81 0,022 0,217 CGP 
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP 55 1,52 0,093 0,218 CGP 
HATADA_METHYLATED_IN_LUNG_CANCER_DN 35 1,52 0,059 0,219 CGP 
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN 50 1,89 0,009 0,220 CGP 
CHROMATIN_ASSEMBLY_OR_DISASSEMBLY 26 1,79 0,007 0,220 Gobp 
WEST_ADRENOCORTICAL_CARCINOMA_VS_ADENOMA_UP 21 1,52 0,056 0,220 CGP 
CAFFAREL_RESPONSE_TO_THC_DN 31 1,52 0,051 0,221 CGP 
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP 51 1,85 0,002 0,221 CGP 
CAMP_UP.V1_UP 189 1,40 0,076 0,222 C6 
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS 64 1,41 0,125 0,222 Reactome 
TOMIDA_METASTASIS_UP 24 1,51 0,045 0,222 CGP 
NUCLEAR_EXPORT 32 1,88 0,000 0,223 Gobp 
MALONEY_RESPONSE_TO_17AAG_DN 77 1,51 0,075 0,223 CGP 
RICKMAN_TUMOR_DIFFERENTIATED_MODERATELY_VS_POORLY_DN 15 1,51 0,071 0,224 CGP 
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PUJANA_XPRSS_INT_NETWORK 163 1,51 0,085 0,224 CGP 
BOYAULT_LIVER_CANCER_SUBCLASS_G23_UP 51 1,51 0,118 0,225 CGP 
NOVAK_MET 16 1,36 0,149 0,225 HCCsignatures 
ZHAN_VARIABLE_EARLY_DIFFERENTIATION_GENES_DN 30 1,51 0,052 0,225 CGP 
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_ORIGIN_COMPLEX 54 1,40 0,156 0,225 Reactome 
DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_UP 72 1,51 0,011 0,225 CGP 
COLLER_MYC_TARGETS_UP 25 1,51 0,057 0,225 CGP 
PEART_HDAC_PROLIFERATION_CLUSTER_UP 55 1,51 0,050 0,225 CGP 
REACTOME_TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM 53 1,40 0,126 0,226 Reactome 
HEIDENBLAD_AMPLIFIED_IN_PANCREATIC_CANCER 30 1,86 0,004 0,226 CGP 
PUIFFE_INVASION_INHIBITED_BY_ASCITES_UP 78 1,51 0,041 0,226 CGP 
SINGLE_STRANDED_DNA_BINDING 33 1,44 0,073 0,226 Gomf 
CELLULAR_LOCALIZATION 364 1,47 0,014 0,227 Gobp 
REACTOME_PHOSPHORYLATION_OF_THE_APC_C 17 1,40 0,133 0,227 Reactome 
NEGATIVE_REGULATION_OF_METABOLIC_PROCESS 256 1,46 0,012 0,228 Gobp 
REACTOME_ASSOCIATION_OF_TRIC_CCT_WITH_TARGET_PROTEINS_DURING_BIOSYNTHESIS 26 1,40 0,081 0,228 Reactome 
ATPASE_ACTIVITY_COUPLED_TO_TRANSMEMBRANE_MOVEMENT_OF_IONS 24 1,44 0,067 0,228 Gomf 
REACTOME_HOMOLOGOUS_RECOMBINATION_REPAIR_OF_REPLICATION_INDEPENDENT_DOUBLE_STRAND_BREAKS 16 1,40 0,108 0,229 Reactome 
SU_TESTIS 74 1,50 0,083 0,230 CGP 
WU_HBX_TARGETS_1_DN 23 1,50 0,045 0,230 CGP 
MELLMAN_TUT1_TARGETS_UP 19 1,50 0,057 0,230 CGP 
BREUHAHN_GROWTH_FACTOR_SIGNALING_IN_LIVER_CANCER 21 1,50 0,054 0,231 CGP 
WHITFIELD_CELL_CYCLE_LITERATURE 44 1,50 0,139 0,231 CGP 
PECE_MAMMARY_STEM_CELL_DN 134 1,50 0,074 0,231 CGP 
AAGCACA,MIR-218 394 1,33 0,030 0,232 MIR 
GRADE_METASTASIS_DN 44 1,49 0,079 0,232 CGP 
AGGAGTG,MIR-483 65 1,35 0,076 0,233 MIR 
SIG_CHEMOTAXIS 45 1,30 0,099 0,234 SignalGateway 
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REACTOME_PI_3K_CASCADE 54 1,38 0,067 0,234 Reactome 
REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_REGION_ 43 1,39 0,135 0,235 Reactome 
TACGGGT,MIR-99A,MIR-100,MIR-99B 23 1,35 0,091 0,235 MIR 
REACTOME_DOWNSTREAM_SIGNAL_TRANSDUCTION 91 1,39 0,042 0,235 Reactome 
REACTOME_BIOSYNTHESIS_OF_THE_N_GLYCAN_PRECURSOR_DOLICHOL_LIPID_LINKED_OLIGOSACCHARIDE_LLO_AND_TRANSFER_T
O_A_NASCENT_PROTEIN 26 1,38 0,120 0,235 Reactome 
GGGATGC,MIR-324-5P 49 1,51 0,034 0,236 MIR 
GENERAL_RNA_POLYMERASE_II_TRANSCRIPTION_FACTOR_ACTIVITY 32 1,42 0,064 0,236 Gomf 
REACTOME_PERK_REGULATED_GENE_EXPRESSION 27 1,38 0,114 0,237 Reactome 
REACTOME_REGULATION_OF_MRNA_STABILITY_BY_PROTEINS_THAT_BIND_AU_RICH_ELEMENTS 80 1,39 0,123 0,237 Reactome 
BIOCARTA_MPR_PATHWAY 33 1,45 0,076 0,237 BIOCARTA 
ODONNELL_TARGETS_OF_MYC_AND_TFRC_DN 45 1,49 0,134 0,237 CGP 
REACTOME_MRNA_CAPPING 27 1,38 0,116 0,237 Reactome 
CACTGTG,MIR-128A,MIR-128B 333 1,33 0,041 0,238 MIR 
REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION 72 1,38 0,064 0,238 Reactome 
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_UP 85 1,89 0,005 0,238 CGP 
ATGCTGC,MIR-103,MIR-107 214 1,37 0,034 0,238 MIR 
NUCLEAR_ENVELOPE_ENDOPLASMIC_RETICULUM_NETWORK 94 1,32 0,126 0,239 GOcc 
GGGACCA,MIR-133A,MIR-133B 196 1,32 0,083 0,239 MIR 
WOO_LIVER_CANCER_CHOLANGIOCA_LIKE_UP 233 1,32 0,197 0,239 HCCsignatures 
CONRAD_STEM_CELL 39 1,49 0,041 0,240 CGP 
PROTEIN_AMINO_ACID_O_LINKED_GLYCOSYLATION 18 1,45 0,054 0,240 Gobp 
NEGATIVE_REGULATION_OF_CELLULAR_METABOLIC_PROCESS 254 1,45 0,020 0,240 Gobp 
ACAGGGT,MIR-10A,MIR-10B 123 1,33 0,081 0,240 MIR 
CAGCAGG,MIR-370 150 1,35 0,072 0,240 MIR 
GEORGES_CELL_CYCLE_MIR192_TARGETS 61 1,48 0,066 0,241 CGP 
BILD_MYC_ONCOGENIC_SIGNATURE 195 1,48 0,042 0,242 CGP 
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_TURQUOISE_DN 52 1,48 0,113 0,242 CGP 
CCACACA,MIR-147 62 1,34 0,075 0,242 MIR 
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BIOCARTA_EIF_PATHWAY 16 1,44 0,104 0,243 BIOCARTA 
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_UP 66 1,48 0,057 0,243 CGP 
ST_INTEGRIN_SIGNALING_PATHWAY 81 1,29 0,095 0,243 SignalTransductionKE 
REGULATION_OF_DNA_METABOLIC_PROCESS 43 1,44 0,059 0,243 Gobp 
POMEROY_MEDULLOBLASTOMA_PROGNOSIS_UP 45 1,48 0,048 0,243 CGP 
BLUM_RESPONSE_TO_SALIRASIB_UP 243 1,48 0,023 0,243 CGP 
RUIZ_TNC_TARGETS_DN 141 1,48 0,106 0,243 CGP 
LE_NEURONAL_DIFFERENTIATION_DN 19 1,47 0,103 0,244 CGP 
GRADE_COLON_VS_RECTAL_CANCER_DN 54 1,47 0,055 0,244 CGP 
CTCAGGG,MIR-125B,MIR-125A 324 1,34 0,065 0,245 MIR 
AGUIRRE_PANCREATIC_CANCER_COPY_NUMBER_UP 286 1,48 0,040 0,245 CGP 
ACCAATC,MIR-509 46 1,37 0,064 0,245 MIR 
WANG_RESPONSE_TO_GSK3_INHIBITOR_SB216763_DN 352 1,48 0,064 0,245 CGP 
TTGGGAG,MIR-150 89 1,36 0,070 0,247 MIR 
REACTOME_TRANSPORT_OF_MATURE_MRNA_DERIVED_FROM_AN_INTRONLESS_TRANSCRIPT 33 1,37 0,131 0,248 Reactome 
PIGMENT_METABOLIC_PROCESS 18 1,44 0,081 0,248 Gobp 
REACTOME_HOST_INTERACTIONS_OF_HIV_FACTORS 120 1,36 0,144 0,248 Reactome 
BIOCARTA_BARRESTIN_SRC_PATHWAY 15 1,74 0,005 0,248 BIOCARTA 
GTGCCAA,MIR-96 302 1,37 0,032 0,249 MIR 
LIU_SOX4_TARGETS_DN 300 1,47 0,037 0,249 CGP 
CELL_CORTEX 39 1,31 0,114 0,249 GOcc 
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON 141 1,47 0,081 0,249 CGP 
CCATCCA,MIR-432 55 1,37 0,065 0,249 MIR 
REACTOME_TRNA_AMINOACYLATION 42 1,36 0,142 0,250 Reactome 
      
      
Gene sets enriched (FDR<0.25) in patients with mortality index < 230 
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p-value FDR(<0.25) Database (http://www.broadinstitute.org/gsea/msigdb/) 
KEGG_DRUG_METABOLISM_OTHER_ENZYMES 42 -1,80 0,003 0,033 KEGG 
KEGG_STEROID_HORMONE_BIOSYNTHESIS 46 -1,82 0,005 0,033 KEGG 
KEGG_PRIMARY_IMMUNODEFICIENCY 35 -1,78 0,002 0,035 KEGG 
KEGG_TRYPTOPHAN_METABOLISM 40 -1,77 0,009 0,035 KEGG 
KEGG_TYPE_I_DIABETES_MELLITUS 40 -1,80 0,007 0,036 KEGG 
KEGG_HEMATOPOIETIC_CELL_LINEAGE 85 -1,78 0,007 0,038 KEGG 
KEGG_ALLOGRAFT_REJECTION 35 -1,82 0,007 0,038 KEGG 
KEGG_ABC_TRANSPORTERS 43 -1,75 0,007 0,040 KEGG 
KEGG_ALPHA_LINOLENIC_ACID_METABOLISM 17 -1,74 0,011 0,040 KEGG 
KEGG_GRAFT_VERSUS_HOST_DISEASE 36 -1,74 0,009 0,040 KEGG 
KEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS 20 -1,83 0,004 0,044 KEGG 
KEGG_AUTOIMMUNE_THYROID_DISEASE 48 -1,86 0,007 0,047 KEGG 
KEGG_VIRAL_MYOCARDITIS 68 -1,71 0,009 0,049 KEGG 
KEGG_RETINOL_METABOLISM 55 -1,83 0,009 0,052 KEGG 
KEGG_CELL_ADHESION_MOLECULES_CAMS 130 -1,88 0,000 0,053 KEGG 
KEGG_DRUG_METABOLISM_CYTOCHROME_P450 61 -1,70 0,018 0,054 KEGG 
KEGG_LINOLEIC_ACID_METABOLISM 27 -1,69 0,013 0,061 KEGG 
KEGG_PROPANOATE_METABOLISM 32 -1,66 0,028 0,068 KEGG 
KEGG_ASCORBATE_AND_ALDARATE_METABOLISM 17 -1,63 0,027 0,069 KEGG 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 77 -1,63 0,042 0,069 KEGG 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 98 -1,66 0,006 0,071 KEGG 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 67 -1,65 0,059 0,071 KEGG 
KEGG_ASTHMA 28 -1,63 0,043 0,072 KEGG 
KEGG_ARACHIDONIC_ACID_METABOLISM 55 -1,63 0,007 0,073 KEGG 
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 31 -1,64 0,027 0,074 KEGG 
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KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 127 -1,61 0,032 0,075 KEGG 
KEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450 60 -1,64 0,033 0,077 KEGG 
KEGG_STARCH_AND_SUCROSE_METABOLISM 40 -1,90 0,002 0,078 KEGG 
KEGG_BETA_ALANINE_METABOLISM 22 -1,60 0,047 0,080 KEGG 
HOSHIDA_S3 256 -1,74 0,033 0,093 HCCsignatures 
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION 45 -1,56 0,061 0,105 KEGG 
YE_LIVER_CANCER_INTRAHEPATIC_METS 22 -1,56 0,021 0,106 HCCsignatures 
CHIANG_LIVER_CANCER_SUBCLASS_POLYSOMY7 59 -1,60 0,046 0,128 HCCsignatures 
FURUKAWA_DUSP6_TARGETS_PCI35_UP 73 -1,94 0,002 0,134 CGP 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 251 -1,52 0,054 0,136 KEGG 
KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS 16 -1,51 0,087 0,136 KEGG 
WINTER_HYPOXIA_DN 49 -1,91 0,000 0,140 CGP 
ATM_DN.V1_DN 144 -1,64 0,002 0,140 c6 
SANA_RESPONSE_TO_IFNG_UP 73 -1,89 0,002 0,145 CGP 
CATION_HOMEOSTASIS 107 -1,69 0,007 0,149 Gobp 
CHEMICAL_HOMEOSTASIS 153 -1,61 0,005 0,153 Gobp 
ION_HOMEOSTASIS 127 -1,62 0,007 0,154 Gobp 
IMMUNE_SYSTEM_PROCESS 322 -1,70 0,014 0,155 Gobp 
KRAS.300_UP.V1_DN 134 -1,61 0,010 0,156 c6 
CELLULAR_HOMEOSTASIS 145 -1,62 0,000 0,159 Gobp 
DETECTION_OF_STIMULUS_INVOLVED_IN_SENSORY_PERCEPTION 21 -1,69 0,019 0,159 Gobp 
BIOCARTA_IL17_PATHWAY 15 -1,81 0 0,159 BIOCARTA 
POSITIVE_REGULATION_OF_TRANSLATION 34 -1,67 0,016 0,161 Gobp 
REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS 38 -1,64 0,016 0,162 Gobp 
CYTOKINE_BIOSYNTHETIC_PROCESS 41 -1,62 0,020 0,163 Gobp 
REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 146 -1,71 0,003 0,163 Gobp 
POSITIVE_REGULATION_OF_CYTOKINE_BIOSYNTHETIC_PROCESS 25 -1,73 0,010 0,164 Gobp 
CYTOKINE_METABOLIC_PROCESS 42 -1,60 0,019 0,164 Gobp 
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CELL_ACTIVATION 73 -1,62 0,038 0,164 Gobp 
LOCOMOTORY_BEHAVIOR 94 -1,59 0,021 0,165 Gobp 
MULTI_ORGANISM_PROCESS 160 -1,59 0,008 0,167 Gobp 
LEUKOCYTE_ACTIVATION 66 -1,67 0,026 0,167 Gobp 
REGULATION_OF_LYMPHOCYTE_ACTIVATION 33 -1,65 0,030 0,167 Gobp 
POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS 64 -1,66 0,012 0,167 Gobp 
PTEN_DN.V1_DN 174 -1,65 0,003 0,167 c6 
POSITIVE_REGULATION_OF_T_CELL_ACTIVATION 21 -1,59 0,039 0,167 Gobp 
POSITIVE_REGULATION_OF_IMMUNE_RESPONSE 28 -1,63 0,025 0,168 Gobp 
RESPONSE_TO_OTHER_ORGANISM 81 -1,62 0,026 0,168 Gobp 
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 113 -1,48 0,051 0,168 KEGG 
T_CELL_PROLIFERATION 19 -1,67 0,014 0,169 Gobp 
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 75 -1,47 0,054 0,169 KEGG 
GAURNIER_PSMD4_TARGETS 70 -1,87 0,002 0,170 CGP 
CALCIUM_INDEPENDENT_CELL_CELL_ADHESION 22 -1,58 0,018 0,171 Gobp 
LYMPHOCYTE_ACTIVATION 58 -1,63 0,032 0,171 Gobp 
ADAPTIVE_IMMUNE_RESPONSE 24 -1,57 0,035 0,171 Gobp 
CELLULAR_CATION_HOMEOSTASIS 104 -1,71 0,003 0,174 Gobp 
SODIUM_ION_TRANSPORT 22 -1,65 0,013 0,175 Gobp 
ADAPTIVE_IMMUNE_RESPONSE_GO_0002460 23 -1,57 0,041 0,175 Gobp 
REGULATION_OF_T_CELL_PROLIFERATION 16 -1,63 0,021 0,176 Gobp 
CALCIUM_MEDIATED_SIGNALING 15 -1,57 0,040 0,179 Gobp 
DEFENSE_RESPONSE 257 -1,73 0,005 0,180 Gobp 
T_CELL_ACTIVATION 42 -1,71 0,016 0,183 Gobp 
REGULATION_OF_IMMUNE_RESPONSE 32 -1,56 0,038 0,183 Gobp 
KEGG_JAK_STAT_SIGNALING_PATHWAY 150 -1,45 0,075 0,185 KEGG 
RESPONSE_TO_DRUG 20 -1,74 0,007 0,186 Gobp 
KEGG_BUTANOATE_METABOLISM 34 -1,44 0,122 0,187 KEGG 
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KEGG_ONE_CARBON_POOL_BY_FOLATE 17 -1,45 0,071 0,187 KEGG 
IMMUNE_RESPONSE 228 -1,81 0,005 0,194 Gobp 
CAIRO_HEPATOBLASTOMA_DN 263 -1,84 0,017 0,199 CGP 
KEGG_LEISHMANIA_INFECTION 68 -1,42 0,119 0,202 KEGG 
KEGG_FATTY_ACID_METABOLISM 39 -1,42 0,137 0,204 KEGG 
KRAS.600.LUNG.BREAST_UP.V1_DN 275 -1,52 0,013 0,210 c6 
RESPONSE_TO_VIRUS 49 -1,54 0,052 0,210 Gobp 
CELLULAR_DEFENSE_RESPONSE 53 -1,74 0,005 0,213 Gobp 
BIOCARTA_IL12_PATHWAY 21 -1,63 0,021 0,214 BIOCARTA 
KEGG_HISTIDINE_METABOLISM 29 -1,40 0,110 0,215 KEGG 
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE 50 -1,77 0,007 0,215 Reactome 
REGULATION_OF_DEFENSE_RESPONSE 19 -1,84 0,000 0,216 Gobp 
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 107 -1,39 0,088 0,218 KEGG 
KEGG_CHEMOKINE_SIGNALING_PATHWAY 179 -1,39 0,095 0,219 KEGG 
INFLAMMATORY_RESPONSE 124 -1,53 0,048 0,223 Gobp 
JNK_DN.V1_UP 184 -1,50 0,008 0,225 c6 
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL 60 -1,83 0,005 0,228 Reactome 
KRAS.50_UP.V1_DN 45 -1,52 0,042 0,232 c6 
KRAS.LUNG.BREAST_UP.V1_DN 135 -1,53 0,014 0,233 c6 
ACTIVATION_OF_IMMUNE_RESPONSE 16 -1,50 0,060 0,233 Gobp 
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN 66 -1,81 0,005 0,235 CGP 
PEPTIDYL_TYROSINE_PHOSPHORYLATION 26 -1,50 0,038 0,236 Gobp 
REACTOME_PHASE1_FUNCTIONALIZATION_OF_COMPOUNDS 69 -1,73 0,010 0,236 Reactome 
KRAS.LUNG_UP.V1_DN 138 -1,72 0,005 0,238 c6 
REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION 17 -1,52 0,032 0,238 Gobp 
POSITIVE_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 49 -1,77 0,000 0,239 Gobp 
POSITIVE_REGULATION_OF_LYMPHOCYTE_ACTIVATION 23 -1,50 0,073 0,240 Gobp 
T_CELL_DIFFERENTIATION 15 -1,51 0,075 0,240 Gobp 
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NEGATIVE_REGULATION_OF_TRANSCRIPTION_FACTOR_ACTIVITY 15 -1,51 0,052 0,240 Gobp 
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON 26 -1,37 0,163 0,242 HCCsignatures 
REACTOME_BIOLOGICAL_OXIDATIONS 124 -1,79 0,009 0,243 Reactome 
REGULATION_OF_RESPONSE_TO_STIMULUS 57 -1,49 0,041 0,243 Gobp 
STEROID_BIOSYNTHETIC_PROCESS 23 -1,50 0,043 0,245 Gobp 
RPS14_DN.V1_UP 188 -1,65 0,026 0,246 c6 
REGULATION_OF_T_CELL_ACTIVATION 27 -1,75 0,010 0,249 Gobp 
BIOCARTA_IL7_PATHWAY 17 -1,71 0,013 0,250 BIOCARTA 
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Supplementary Table 4: Methylation normals versus HCC markers 
    TargetID F UCSC_REFGENE_NAME 
cg18247055 115,196274 SPAG6 
 cg15841063 107,659997 FOXD3 
 cg08441806 102,355967 NKX6-2 
 cg07055616 101,574579 NKX6-2 
 cg25537993 94,4485251 ZSCAN1 
 cg27392792 92,1900185 PTPRN2 
 cg06268694 84,3620216 CELSR1 
 cg05080154 83,1159092 SALL3 
 cg23016129 81,0480221 SPAG6 
 cg17536595 80,961124 RSPH9 
 cg16086620 80,9338937 CHGA 
 cg11068946 79,6668413 NKX6-2 
 cg11823511 79,2613027 BARHL2 
 cg05904135 75,5291113 NKX6-2 
 cg12377139 73,3130122 SPAG6 
 cg19761848 71,6162116 GBX2 
 cg06769546 71,0502262 NKX6-2 
 cg14231297 70,6580049 ZSCAN18 
 cg17996619 68,9151409 NKX6-2 
 cg25032595 68,8557568 CLDN10 
 cg16657538 68,593844 ZNF397OS 
 cg20129213 68,2029 RIMS2 
 cg24426072 67,2347139 TRIL 
 cg16949120 67,181187 NKX6-2 
 cg26923490 65,9478214 KCNA7 
 cg09053680 65,7291766 UTF1 
 cg16823083 65,1968796 WDR8 
 cg19792599 65,0538646 PUS3; DDX25 
cg22557662 65,0285326 PPP1R14A 
 cg02571816 63,6671985 PPP1R14A 
 cg20232102 63,6459583 PPP1R14A 
 cg09515953 62,7233754 PPP1R14A 
 cg24659054 61,620433 NKX6-2 
 cg00884093 61,4700382 CELSR1 
 cg13902210 61,1612045 KCNC4 
 cg11377136 60,9956336 PKDREJ 
 cg16648062 60,2275723 RIMS2 
 cg23246885 59,4021644 FZD7 
 cg14823851 59,1013917 TBX4 
 cg15611336 59,0363678 RPP25 
 cg09894698 58,7904188 ASCL2 
 cg13879483 58,0081957 USP44 
 cg22158769 57,7483782 LOC375196 
 cg05495949 57,5494509 RADIL 
 cg01566592 56,9526169 RIMS2 
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cg12296772 56,8808456 MTMR7 
 cg10171448 56,6985154 NKX6-2 
 cg22796507 56,3730728 FOXE3 
 cg20449685 55,7916996 ZSCAN1 
 cg17003293 55,7436675 INSM2 
 cg03323696 55,3095034 PDE4D 
 cg13564825 55,0564946 PPP1R14A 
 cg24154839 54,5704099 GABRA4 
 cg15466862 54,3128061 SOX1 
 cg01281911 54,1375638 FOXE3 
 cg20106459 54,1074349 COX6B2 
 cg19499748 53,9433272 TRIL 
 cg06572160 53,3622836 KCNC3 
 cg15912800 53,1664243 MIR196B 
 cg01227537 52,7686596 ZIC1 
 cg11173146 51,8117269 EFNB2 
 cg01923218 50,8068481 CCDC67 
 cg14473102 50,503657 HOXD8 
 cg14709460 50,3418651 TRIL 
 cg04823311 50,337962 TRIL 
 cg01384488 49,871573 NKX6-2 
 cg20809087 49,6784281 BRUNOL6 
 cg26844246 49,3630032 TLX3 
 cg23842255 49,2134877 NEFH 
 cg16582779 49,144746 FOXG1 
 cg05095158 48,8953094 RASSF10 
 cg12744820 48,8747092 OLIG3 
 cg12188986 48,874371 CCDC67 
 cg09260089 48,7739829 NKX6-2 
 cg18862481 48,7339431 TRH 
 cg06648277 48,6404743 NKX6-2 
 cg00699945 48,5832305 NKX6-2 
 cg16087093 48,3924322 FOXI1 
 cg19852958 48,1218342 NKX3-2 
 cg25720804 48,0131804 TLX3 
 cg15304699 47,9957787 NKX6-2 
 cg10700424 47,9808215 GLB1L2 
 cg04786857 47,8727968 SPDYA 
 cg14251622 47,5340801 INSM2 
 cg26476852 47,1514509 HOXA9 
 cg02578368 47,1487038 HIST1H3F; HIST1H2BH 
cg27362525 46,9043468 ZNF232 
 cg05057720 46,897471 CLEC14A 
 cg08288811 46,8741491 PCDHA3 
 cg26460092 46,7067947 TM6SF1 
 cg10655046 46,6314305 FOXD4L1 
 cg12206199 46,6014801 LOC375196 
 cg11935147 46,5867978 PDE4DIP 
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cg18233405 46,5605228 TSPYL5 
 cg03468349 46,4721334 SH3YL1; ACP1 
cg18815943 46,4616068 FOXE3 
 cg03840594 46,1628793 POU3F2 
 cg23923856 46,0823209 WNT2B 
 cg10526374 45,5512381 ASCL2 
 cg18932798 45,5109799 INA 
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Supplementary Table 5: Methylation normals versus HCC markers (common in Heptromic and Song cohorts) 
    TargetID F UCSC_REFGENE_NAME 
cg18247055 115,196274 SPAG6 
 cg15841063 107,659997 FOXD3 
 cg05080154 83,1159092 SALL3 
 cg23016129 81,0480221 SPAG6 
 cg05904135 75,5291113 NKX6-2 
 cg12377139 73,3130122 SPAG6 
 cg14231297 70,6580049 ZSCAN18 
 cg25032595 68,8557568 CLDN10 
 cg16657538 68,593844 ZNF397OS 
 cg20129213 68,2029 RIMS2 
 cg24426072 67,2347139 TRIL 
 cg16949120 67,181187 NKX6-2 
 cg16823083 65,1968796 WDR8 
 cg19792599 65,0538646 PUS3; DDX25 
cg24659054 61,620433 NKX6-2 
 cg00884093 61,4700382 CELSR1 
 cg16648062 60,2275723 RIMS2 
 cg23246885 59,4021644 FZD7 
 cg09894698 58,7904188 ASCL2 
 cg13879483 58,0081957 USP44 
 cg05495949 57,5494509 RADIL 
 cg01566592 56,9526169 RIMS2 
 cg12296772 56,8808456 MTMR7 
 cg10171448 56,6985154 NKX6-2 
 cg22796507 56,3730728 FOXE3 
 cg24154839 54,5704099 GABRA4 
 cg01281911 54,1375638 FOXE3 
 cg19499748 53,9433272 TRIL 
 cg11173146 51,8117269 EFNB2 
 cg01923218 50,8068481 CCDC67 
 cg04823311 50,337962 TRIL 
 cg01384488 49,871573 NKX6-2 
 cg20809087 49,6784281 BRUNOL6 
 cg05095158 48,8953094 RASSF10 
 cg09260089 48,7739829 NKX6-2 
 cg15304699 47,9957787 NKX6-2 
 cg27362525 46,9043468 ZNF232 
 cg26460092 46,7067947 TM6SF1 
 cg10655046 46,6314305 FOXD4L1 
 cg11935147 46,5867978 PDE4DIP 
 cg18233405 46,5605228 TSPYL5 
 cg03468349 46,4721334 SH3YL1; ACP1 
cg10526374 45,5512381 ASCL2 
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Supplementary Table 6: Candidate novel epidrivers during hepatocarcinogensis.  
Top 500 F-scored between HCC and normal liver 
          TargetID F score UCSC_REFGENE_NAME UCSC_REFGENE_GROUP 
     cg18247055 115,196274 SPAG6 TSS200 
      cg15841063 107,659997 FOXD3 1stExon 
      cg08441806 102,355967 NKX6-2 1stExon 
      cg07055616 101,574579 NKX6-2 TSS1500 
      cg25537993 94,4485251 ZSCAN1 TSS1500 
      cg27392792 92,1900185 PTPRN2 TSS1500 
      cg06268694 84,3620215 CELSR1 1stExon 
      cg05080154 83,1159092 SALL3 TSS1500 
      cg23016129 81,0480221 SPAG6 TSS200 
      cg17536595 80,961124 RSPH9 1stExon 
      cg16086620 80,9338937 CHGA 1stExon; 5'UTR 
     cg11068946 79,6668413 NKX6-2 1stExon 
      cg11823511 79,2613027 BARHL2 TSS1500 
      cg05904135 75,5291113 NKX6-2 1stExon 
      cg12377139 73,3130122 SPAG6 TSS200 
      cg19761848 71,6162116 GBX2 TSS200 
      cg06769546 71,0502262 NKX6-2 TSS1500 
      cg14231297 70,6580049 ZSCAN18 TSS200 
      cg17996619 68,9151409 NKX6-2 TSS1500 
      cg25032595 68,8557568 CLDN10 5'UTR; 1stExon 
     cg16657538 68,593844 ZNF397OS 5'UTR 
      cg20129213 68,2029 RIMS2 TSS1500 
      cg24426072 67,2347139 TRIL 1stExon 
      cg16949120 67,181187 NKX6-2 TSS1500 
      cg26923490 65,9478214 KCNA7 1stExon 
      cg09053680 65,7291766 UTF1 1stExon 
      cg16823083 65,1968796 WDR8 TSS1500 
      cg19792599 65,0538646 PUS3; DDX25 TSS1500; 5'UTR; 1stExon 
     cg22557662 65,0285326 PPP1R14A TSS1500 
      cg02571816 63,6671985 PPP1R14A TSS1500 
      cg20232102 63,6459583 PPP1R14A TSS200 
      cg09515953 62,7233754 PPP1R14A TSS200 
      cg24659054 61,620433 NKX6-2 TSS1500 
      cg00884093 61,4700382 CELSR1 1stExon 
      cg13902210 61,1612045 KCNC4 1stExon 
      cg11377136 60,9956336 PKDREJ 1stExon 
      cg16648062 60,2275723 RIMS2 TSS1500 
      cg23246885 59,4021644 FZD7 1stExon 
      cg14823851 59,1013917 TBX4 TSS1500 
      cg15611336 59,0363678 RPP25 1stExon 
      cg09894698 58,7904188 ASCL2 1stExon 
      cg13879483 58,0081957 USP44 TSS1500; 5'UTR 
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cg22158769 57,7483782 LOC375196 TSS200 
      cg05495949 57,5494509 RADIL 5'UTR 
      cg01566592 56,9526169 RIMS2 TSS200 
      cg12296772 56,8808456 MTMR7 TSS200 
      cg10171448 56,6985154 NKX6-2 TSS1500 
      cg22796507 56,3730728 FOXE3 1stExon 
      cg20449685 55,7916996 ZSCAN1 5'UTR 
      cg17003293 55,7436675 INSM2 1stExon 
      cg03323696 55,3095034 PDE4D 1stExon 
      cg13564825 55,0564946 PPP1R14A TSS200 
      cg24154839 54,5704099 GABRA4 TSS200 
      cg15466862 54,3128061 SOX1 1stExon 
      cg01281911 54,1375638 FOXE3 1stExon 
      cg20106459 54,1074349 COX6B2 5'UTR; 1stExon 
     cg19499748 53,9433272 TRIL 1stExon; 5'UTR 
     cg06572160 53,3622836 KCNC3 1stExon 
      cg15912800 53,1664243 MIR196B TSS200 
      cg01227537 52,7686596 ZIC1 TSS200 
      cg11173146 51,8117269 EFNB2 TSS200 
      cg01923218 50,806848 CCDC67 1stExon; 5'UTR 
     cg14473102 50,503657 HOXD8 TSS200 
      cg14709460 50,3418651 TRIL TSS200 
      cg04823311 50,337962 TRIL 1stExon 
      cg01384488 49,871573 NKX6-2 TSS1500 
      cg20809087 49,6784281 BRUNOL6 1stExon; 5'UTR 
     cg26844246 49,3630032 TLX3 TSS200 
      cg23842255 49,2134877 NEFH 1stExon 
      cg16582779 49,144746 FOXG1 1stExon 
      cg05095158 48,8953094 RASSF10 1stExon 
      cg12744820 48,8747092 OLIG3 1stExon 
      cg12188986 48,874371 CCDC67 5'UTR; 1stExon 
     cg09260089 48,7739829 NKX6-2 TSS1500 
      cg18862481 48,7339431 TRH 5'UTR; 1stExon 
     cg06648277 48,6404743 NKX6-2 TSS1500 
      cg00699945 48,5832305 NKX6-2 TSS1500 
      cg16087093 48,3924322 FOXI1 1stExon 
      cg19852958 48,1218342 NKX3-2 1stExon 
      cg25720804 48,0131804 TLX3 1stExon 
      cg15304699 47,9957787 NKX6-2 TSS1500 
      cg10700424 47,9808215 GLB1L2 1stExon; 5'UTR 
     cg04786857 47,8727968 SPDYA 5'UTR 
      cg14251622 47,5340801 INSM2 1stExon 
      cg26476852 47,1514509 HOXA9 1stExon 
      cg02578368 47,1487038 HIST1H3F; HIST1H2BH 1stExon; TSS1500 
     cg27362525 46,9043468 ZNF232 5'UTR 
      cg05057720 46,897471 CLEC14A 1stExon 
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cg08288811 46,8741491 PCDHA3 1stExon 
      cg26460092 46,7067947 TM6SF1 5'UTR; 1stExon 
     cg10655046 46,6314305 FOXD4L1 1stExon 
      cg12206199 46,6014801 LOC375196 TSS200 
      cg11935147 46,5867978 PDE4DIP 1stExon 
      cg18233405 46,5605228 TSPYL5 5'UTR; 1stExon 
     cg03468349 46,4721334 SH3YL1; ACP1 TSS200; TSS1500 
     cg18815943 46,4616068 FOXE3 1stExon 
      cg03840594 46,1628793 POU3F2 1stExon 
      cg23923856 46,0823209 WNT2B 5'UTR; 1stExon 
     cg10526374 45,5512381 ASCL2 TSS1500 
      cg18932798 45,5109799 INA 1stExon 
      cg12781700 45,5046189 C17orf104 TSS200 
      cg13717446 45,4394088 LOC146880 TSS200 
      cg22538054 45,3671719 USP44 5'UTR 
      cg24604013 45,1581521 SOX1 TSS1500 
      cg18724565 45,1001369 FSCN1 1stExon 
      cg22740547 45,0859848 RASSF10 1stExon 
      cg14688104 45,0574393 KCNS2 1stExon;5'UTR 
     cg20049415 44,8848702 NKX2-4 1stExon 
      cg18854169 44,8736462 RBP3 1stExon 
      cg23806621 44,7717707 BHLHE23 TSS200 
      cg21790626 44,6564055 ZNF154 1stExon; 5'UTR 
     cg08558397 44,6058753 PRKAR1B 5'UTR; 1stExon 
     cg07759394 44,5744915 GLB1L2 1stExon; 5'UTR 
     cg19464917 44,4608216 ISL2 TSS1500 
      cg14715697 44,422618 HRNBP3 5'UTR 
      cg24368848 44,3727806 ZSCAN1 TSS1500 
      cg07382554 44,2958466 SALL3 TSS200 
      cg11498870 44,2463711 DCAF4L2 5'UTR; 1stExon 
     cg22789900 44,2458408 MIXL1 1stExon 
      cg15834072 43,9776574 DCHS2 1stExon 
      cg19078576 43,7897175 BASP1; LOC285696 1stExon; 5'UTR; TSS1500 
     cg11176990 43,7264955 LOC375196 TSS200 
      cg17630392 43,5558758 NPR3 1stExon 
      cg13794530 43,3355475 VIPR2 5'UTR; 1stExon 
     cg20270188 43,2837182 BCAN 5'UTR; 1stExon 
     cg05546863 43,2492895 CMTM2 TSS200 
      cg13204512 43,1078348 RNF135 1stExon 
      cg03063639 43,0486994 TM6SF1 5'UTR; 1stExon 
     cg10715223 42,9894128 SNX31 1stExon; 5'UTR 
     cg12783819 42,9754246 SEPT9 5'UTR 
      cg27049766 42,888811 ZNF154 1stExon; 5'UTR 
     cg14625175 42,793574 HOXA10 TSS200 
      cg19809499 42,75008 FOXE3 1stExon 
      cg06707978 42,6364026 ZIK1 TSS1500 
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cg18016181 42,5122885 FOXD4 1stExon 
      cg17264670 42,3343436 RGS17 TSS1500 
      cg20275528 42,3201694 SEPT9 1stExon; 5'UTR 
     cg08833577 42,2253901 VAX1 TSS1500 
      cg12127472 42,1053422 C17orf104 TSS200 
      cg18758796 42,0092163 PDLIM4 5'UTR; 1stExon 
     cg20146541 41,9828195 TRIM58 1stExon 
      cg16924337 41,836897 RGS17 TSS1500 
      cg01303723 41,8185941 NKX6-2 TSS1500 
      cg01532168 41,7557301 KCNK9 TSS1500 
      cg16579555 41,7554184 RNF135 1stExon 
      cg09639151 41,6465827 PCDHGA12 1stExon 
      cg06158650 41,6201084 TBX15 5'UTR 
      cg08304190 41,5324301 MIR663 TSS200 
      cg15157455 41,522442 HIST2H2BF TSS1500 
      cg10791343 41,5178219 POM121L12 TSS200 
      cg21187554 41,4787871 ANKRD18A; C9orf122 1stExon; 5'UTR; TSS1500 
     cg03757145 41,3406134 CDKL2 TSS200 
      cg06469345 41,2834865 DRD5 TSS200 
      cg25485875 41,1008931 NKX6-2 TSS1500 
      cg21426003 41,05736 GBX2 TSS200 
      cg08876434 40,7882405 RASSF10 TSS200 
      cg06525651 40,6568541 FAM196A 5'UTR; 1stExon 
     cg19867649 40,625043 DKK3 1stExon; TSS1500; 5'UTR 
     cg13703049 40,6172304 HOXA10 1stExon 
      cg27252696 40,5648939 SIM1 TSS1500 
      cg11595545 40,5157775 KCNA3 5'UTR; 1stExon 
     cg26124318 40,46454 ADAM32 1stExon; 5'UTR 
     cg04034767 40,3083063 GRASP 1stExon 
      cg10703826 40,2684444 TBX15 1stExon; 5'UTR 
     cg26609631 40,1972767 GSX1 1stExon; 5'UTR 
     cg22399133 40,1945349 CRYGD 1stExon; 5'UTR 
     cg00661485 40,1484098 FOXI1 1stExon 
      cg21264189 40,0026204 POU4F1 TSS200 
      cg02339682 39,9972653 BEND6; DST TSS1500; TSS200 
     cg02011074 39,9555663 DNM3 TSS200 
      cg04021697 39,8994563 WDR8 TSS1500 
      cg23543123 39,8609345 SLC10A4 5'UTR; 1stExon 
     cg14565725 39,7379085 TBX15 5'UTR; 1stExon 
     cg11667020 39,6495773 NKX2-4 1stExon; 5'UTR 
     cg00399175 39,6420409 FAM59B TSS1500 
      cg00701692 39,5943346 NKX6-2 TSS1500 
      cg18371475 39,3967774 IRX2; C5orf38 1stExon; 5'UTR; TSS1500 
     cg21000072 39,3893728 WDR8 TSS1500 
      cg02604524 39,2661935 CCDC48 1stExon 
      cg13080379 39,2560691 TBX15 5'UTR 
      
Page 75 of 81
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
cg15728256 39,1752644 BMP8B 5'UTR; 1stExon 
     cg02892660 39,1736852 ZNF761 5'UTR 
      cg21647227 39,1592818 TBX15 5'UTR 
      cg26818735 39,0463684 TWIST1 1stExon 
      cg23095743 38,9758458 PITX3 5'UTR 
      cg02823783 38,8450727 DNAH10 TSS200 
      cg08171351 38,7572269 CECR6 1stExon 
      cg12973941 38,7529118 NKX3-2 1stExon 
      cg25951981 38,7360319 GABRA4 TSS200 
      cg07609862 38,7001079 MTNR1B 1stExon 
      cg05022673 38,6924289 DST; BEND6 TSS200; TSS1500 
     cg03905847 38,6436872 NKX6-2 TSS1500 
      cg07703401 38,5681797 HBQ1 1stExon; 5'UTR 
     cg04137594 38,5064927 NPBWR2 1stExon 
      cg13604246 38,4202505 ANKMY1 TSS200 
      cg00140112 38,4071003 DLGAP1 1stExon 
      cg12056138 38,3214803 C15orf60 TSS200 
      cg05789704 38,2524205 ADAM32 TSS200 
      cg22447539 38,215801 FSCN1 1stExon 
      cg23054189 38,0037125 TRIM58 1stExon 
      cg21884231 37,9504388 SLC7A14 1stExon; 5'UTR 
     cg02237540 37,9482498 PDE6B 1stExon 
      cg02288825 37,8770086 MYT1L 5'UTR 
      cg26822097 37,8618968 psiTPTE22 TSS1500 
      cg04600618 37,8530014 RSPH9 1stExon 
      cg07347092 37,7931989 DNAH10 TSS200 
      cg17295225 37,7898292 OLIG3 1stExon 
      cg00554413 37,6660571 TACSTD2 1stExon 
      cg08726248 37,6264538 DRD4 TSS1500 
      cg09972405 37,6223445 MYT1L 5'UTR 
      cg12315713 37,5826528 CCDC67 1stExon; 5'UTR 
     cg03731268 37,5286648 L1TD1 5'UTR 
      cg22010052 37,4735119 LVRN 1stExon 
      cg02109484 37,4542843 C2orf65 TSS200 
      cg24452347 37,4346899 CNR2 5'UTR 
      cg02401454 37,4342908 HBQ1 1stExon; 5'UTR 
     cg26440289 37,4222512 SNX31 TSS200 
      cg12989128 37,4187562 GDAP1L1 5'UTR; 1stExon 
     cg25920406 37,3825546 FZD8 1stExon 
      cg21588562 37,3760631 FTMT TSS200 
      cg25948690 37,3758334 FGF6 1stExon 
      cg00824018 37,3255229 INA 1stExon 
      cg27583690 37,3179528 NKX6-2 TSS1500 
      cg00352417 37,2766738 FAM43A 1stExon 
      cg26173997 37,2388209 CDKL2 TSS200 
      cg07382920 37,1913054 WDR8; TP73 TSS1500; TSS1500 
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cg07963234 37,1537155 CRMP1 TSS200 
      cg11413039 37,1130676 DDX25; PUS3 1stExon; TSS1500 
     cg24274117 37,1052065 C20orf195 5'UTR 
      cg00926400 37,1014836 BOLL TSS1500 
      cg07783282 37,09456 USP44 5'UTR; TSS1500 
     cg09652652 37,0773363 FAM43A 1stExon 
      cg24613080 37,0274007 ACCN1 TSS1500 
      cg19740859 36,8766554 MYT1L 5'UTR 
      cg21908638 36,8759641 FAM55C TSS200; TSS1500 
     cg21684012 36,7124894 SIM1 TSS1500 
      cg18564989 36,7086189 MIXL1 TSS1500 
      cg22702772 36,5953081 CELSR3 1stExon 
      cg25189564 36,5774284 VIPR2 TSS1500 
      cg14159026 36,5292389 BVES TSS1500; TSS200 
     cg15225844 36,4856463 MYT1L 5'UTR 
      cg02884176 36,4762027 FOXI3 TSS200 
      cg01995480 36,4142281 PHF21B TSS200; TSS1500 
     cg19544662 36,4119767 FOXI3 TSS200 
      cg00939495 36,2748899 DRD5 5'UTR; 1stExon 
     cg13404054 36,2556229 NOTCH3 1stExon 
      cg03129384 36,2473663 FAM196A TSS1500 
      cg04415176 36,2284952 HOXD13 1stExon 
      cg17301902 36,2127857 GNA14 1stExon; 5'UTR 
     cg23208513 36,1569796 RGS22 TSS200 
      cg06848185 36,1435859 SEPT9 5'UTR; TSS1500 
     cg15457058 36,0992319 FOXE3 1stExon 
      cg23881278 36,0922433 DRD2 TSS1500 
      cg22802813 36,0634232 USP44 5'UTR; TSS200 
     cg20616414 35,9473662 WNK2 1stExon 
      cg21825027 35,9383786 ACP1; SH3YL1 TSS1500; TSS200 
     cg07274618 35,8164451 GALR2 TSS200 
      cg07605211 35,727594 SUSD4 TSS1500 
      cg19947104 35,7096892 KCNC1 TSS200 
      cg23501406 35,5266837 DRD4 TSS1500 
      cg24416513 35,3940175 HOXD8 1stExon; 5'UTR 
     cg26595643 35,3827586 VAX1 TSS1500 
      cg21595709 35,3740323 EPHX3 TSS1500 
      cg19355087 35,349024 NKX6-2 TSS1500 
      cg19270505 35,3484099 RUNX3 1stExon; 5'UTR 
     cg02096396 35,3463867 FAM59B TSS1500 
      cg03817667 35,3127158 VSTM2A TSS200 
      cg23920953 35,3042222 C14orf162 TSS1500 
      cg18485193 35,2751304 MYO10 5'UTR; 1stExon 
     cg10602757 35,2308637 FOXD4L1 1stExon; 5'UTR 
     cg24437737 35,1458785 HIST2H2BF TSS1500 
      cg05184938 35,1125033 SEPT9 5'UTR 
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cg13096208 35,0718827 ST8SIA3 1stExon; 5'UTR 
     cg16494597 35,0350621 OR10H1 1stExon 
      cg17366808 34,950746 C15orf60 TSS200 
      cg04138502 34,9358058 ADCY5 TSS200 
      cg13868604 34,9289977 GDAP1L1 1stExon; 5'UTR 
     cg24136205 34,9158489 ZIC5 TSS200 
      cg14443301 34,908965 FTMT TSS200 
      cg21610164 34,8671963 HIST1H2BI 1stExon 
      cg06825142 34,8318276 DRD4 TSS200 
      cg02177231 34,8246065 TBX15 5'UTR 
      cg17259183 34,8144426 NKX6-2 TSS1500 
      cg16896847 34,8007859 MAFA 1stExon 
      cg05603791 34,7664493 FOXI1 1stExon 
      cg24085946 34,6880133 NFASC 5'UTR; 1stExon 
     cg00413617 34,6454826 KCNC1 TSS200 
      cg01354473 34,5947633 HOXA9 1stExon 
      cg20953187 34,4942043 SLC6A20 1stExon 
      cg00613752 34,3990455 GPR6 5'UTR; 1stExon 
     cg03070297 34,3840001 FAM196A TSS200 
      cg27331241 34,3501274 PRKAR1B 5'UTR 
      cg11223367 34,2268517 FAM55C TSS1500; TSS200 
     cg23337116 34,1877298 RASL11B 1stExon; 5'UTR 
     cg13794993 34,1772917 SALL3 1stExon 
      cg14263942 34,1371306 CDKL2 TSS200 
      cg22441312 34,1259982 POM121L12 TSS200 
      cg02567119 34,115651 TLX1NB; TLX1 TSS200; TSS200 
     cg24563094 34,1046342 FAM59B TSS1500 
      cg26477573 34,0921824 EPHX3 1stExon 
      cg14422922 34,0547815 OR2B11 1stExon 
      cg10097295 34,0173797 FOXD3 1stExon 
      cg17512738 33,9921974 POM121L12 TSS200 
      cg00094518 33,9047588 KLF14 1stExon 
      cg20486569 33,8499253 CLDN5 1stExon; 5'UTR 
     cg22681279 33,8497431 NPBWR2 1stExon 
      cg02970297 33,8177341 DPY19L2P2 TSS1500; TSS200 
     cg25984344 33,7710138 FAM196A TSS200 
      cg24680586 33,7546672 INA TSS200 
      cg04321866 33,7359039 EFNB2 TSS1500 
      cg02623400 33,7237525 ELAVL4 5'UTR; 1stExon 
     cg09382601 33,6745044 PDE6B 1stExon 
      cg06425919 33,6640393 MYOD1 1stExon 
      cg04692403 33,619674 TCF21 1stExon 
      cg03929741 33,5910927 EFNB2 TSS1500 
      cg13974632 33,5519342 BDNF 5'UTR 
      cg02485642 33,4033536 MSLNL TSS200 
      cg16561266 33,3600396 LOC146880 TSS200 
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cg20986370 33,3204207 IGFBP7 1stExon 
      cg25331703 33,2944318 LRRK1 TSS200 
      cg06190616 33,2826368 OR2B11 1stExon 
      cg18416576 33,2513758 HOXA10 TSS200 
      cg11594420 33,2205299 TEX101 TSS200 
      cg26560222 33,1720924 DMRTA2 5'UTR; 1stExon 
     cg15790820 33,0963811 ASCL2 TSS1500 
      cg22131234 33,0657047 VSTM2A TSS200 
      cg04084088 33,0605033 RGS9BP 1stExon 
      cg12414557 33,0577761 RNF212 1stExon; 5'UTR 
     cg13562542 33,0536454 GPR27; EIF4E3 1stExon; 5'UTR 
     cg12997720 32,995797 HOXA11 TSS1500 
      cg01878345 32,8945221 POU3F3 TSS200 
      cg09433135 32,8589374 FLJ40125 1stExon 
      cg08097882 32,8354779 POU4F1 1stExon; 5'UTR 
     cg11964564 32,8068615 KCNS2 5'UTR 
      cg08100565 32,7696345 SLC25A36 1stExon; 5'UTR 
     cg20585869 32,7684148 NEFM TSS200; 1stExon 
     cg05777962 32,7641047 OR2B11 1stExon 
      cg05374654 32,7478949 GPR83 TSS200 
      cg01428589 32,7301073 RGS9BP 1stExon 
      cg02553663 32,6449358 SECTM1 5'UTR; 1stExon 
     cg05201970 32,5713141 HCN1 1stExon; 5'UTR 
     cg07558472 32,5240581 CXXC5 5'UTR 
      cg09054633 32,5188616 SPOCK1 5'UTR 
      cg18729357 32,4757751 ZNF702P TSS200 
      cg26949694 32,3545346 BDNF 5'UTR; TSS1500; 1stExon 
     cg24425021 32,3422964 POU4F1 5'UTR; 1stExon 
     cg12215340 32,3195517 ADRA1D 1stExon; 5'UTR 
     cg05506365 32,3146099 POU3F3 1stExon 
      cg14212850 32,2211273 HRNBP3 5'UTR 
      cg02119134 32,1716367 FOXD4L1 1stExon 
      cg07251711 32,1706235 NKX6-2 TSS1500 
      cg21425842 32,1680433 HIST1H4F 1stExon 
      cg13801416 32,0475889 AKR1B1 TSS200 
      cg17703554 31,9401408 DCAF4L2 TSS200 
      cg06763054 31,8938211 MTMR7 1stExon; 5'UTR 
     cg04380519 31,8903012 LIMD2 TSS1500 
      cg12204732 31,8825008 FAM196A TSS200 
      cg07153665 31,8701382 CMTM2 TSS200 
      cg25945732 31,8539666 SH3YL1; ACP1 TSS200; TSS1500 
     cg17300544 31,8532545 SEPT9 TSS200; 5'UTR 
     cg20931042 31,7847764 DRD4 TSS200 
      cg08931647 31,7272939 MSLNL TSS200 
      cg25644556 31,7163966 MIR196B TSS1500 
      cg02849695 31,7023234 CCDC19 TSS200 
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cg06135139 31,6727204 BHLHE23 1stExon 
      cg13428480 31,6283745 VANGL2 TSS200 
      cg25307665 31,6174718 HOXA5 TSS1500 
      cg13878010 31,6080815 ADCY5 1stExon 
      cg19300568 31,5801025 NAT8L TSS1500 
      cg24903183 31,5766073 SNX31 TSS200 
      cg10188823 31,567078 NEFH 1stExon; 5'UTR 
     cg02547394 31,5667747 SOX1 TSS200 
      cg01972751 31,382522 OLIG3 1stExon 
      cg00172597 31,3785144 SUSD4 TSS1500 
      cg02531437 31,2642945 PRLHR TSS200 
      cg12640000 31,2505043 L1TD1 5'UTR 
      cg03289872 31,1740029 ZNF667 TSS1500 
      cg06784108 31,1567296 EFNB2 1stExon 
      cg03242819 31,15478 FAM196A TSS200 
      cg06401019 31,0982367 MIR2277 TSS1500 
      cg27504802 31,0706095 TRIM67 TSS200 
      cg08101407 31,0371384 TSPYL3 TSS200 
      cg24393316 31,0366755 FOXE1 1stExon 
      cg02932314 30,9490219 C17orf104 TSS200 
      cg00384539 30,9453095 PRDM14 TSS200 
      cg26117023 30,9154964 LOXL3 TSS1500 
      cg21872764 30,8961752 CLDN5 1stExon 
      cg25209842 30,87233 FGF8 TSS1500 
      cg24239148 30,8182388 C10orf107 5'UTR; 1stExon 
     cg05652533 30,7596399 DPYSL4 TSS200 
      cg04686953 30,7560675 RNF212 1stExon; 5'UTR 
     cg06377278 30,6585357 RUNX3 1stExon; 5'UTR 
     cg13222752 30,6371636 TMEM90A 5'UTR 
      cg08382774 30,5962545 NKX6-2 TSS1500 
      cg11469098 30,5674649 EFCAB1 5'UTR; 1stExon 
     cg15140703 30,5648703 GPC2; STAG3 TSS1500; TSS200 
     cg14347199 30,55972 NXNL2 1stExon 
      cg14988503 30,5453381 CDKL2 1stExon; 5'UTR 
     cg14719865 30,5448499 SLCO6A1 1stExon 
      cg02306630 30,53482 NKX6-2 TSS1500 
      cg10084644 30,5278909 GPC2; STAG3 TSS1500; TSS200 
     cg14414971 30,5184792 SDK1 TSS200 
      cg07543830 30,5017686 PMEPA1 5'UTR 
      cg24745495 30,4990237 EPHX3 TSS1500 
      cg03172947 30,4850604 DBNDD2 5'UTR; TSS1500 
     cg23353952 30,4797833 NEFH 1stExon 
      cg18342279 30,4682333 ZAR1 1stExon 
      cg16024318 30,4604923 SLC6A7 5'UTR; 1stExon 
     cg15642758 30,3845709 HDGFRP3 TSS1500 
      cg08315202 30,3622628 NPTX2 TSS1500 
      
Page 80 of 81
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
cg17098147 30,3621014 SPAG6 TSS1500 
      cg20787173 30,3339274 EYA4 TSS200 
      cg24432073 30,3172372 CDKL2 5'UTR; 1stExon 
     cg13997645 30,3009728 INSC TSS200 
      cg02310286 30,2946901 DCAF4L2 TSS200 
      cg08369368 30,2908896 NSD1 TSS1500; TSS200 
     cg06829830 30,2904046 RASGRF2 TSS1500 
      cg18560204 30,2638598 BNC1 TSS1500 
      cg15014975 30,2632012 RUNX3 TSS1500 
      cg06922635 30,2599799 ARL9 5'UTR; 1stExon 
     cg19505136 30,2272765 CHL1 5'UTR 
      cg13930892 30,1861893 ASCL2 1stExon; 5'UTR 
     cg17800654 30,1849553 DMRTA2 5'UTR 
      cg12872693 30,1438977 GNB4 5'UTR 
      cg24884142 30,1331278 TBX15 5'UTR; 1stExon 
     cg00529958 30,1266223 ZIC5 TSS200 
      cg15251385 30,1229043 SLC2A14 TSS200 
      cg20810478 30,1027768 TRIM58 1stExon 
      cg10064339 30,0740518 UCP2 5'UTR; 1stExon 
     cg05488632 30,0663204 EPHX3 5'UTR; 1stExon 
     cg26240185 30,0104386 FAR1 TSS200 
      cg15766075 29,9624715 ANKMY1 TSS200 
      cg17241776 29,925124 DLEU7 1stExon 
      cg10171347 29,8041201 NKX6-2 TSS1500 
      cg10661615 29,8016044 PRLHR TSS200 
      cg06122660 29,7821895 SLC2A14 TSS200 
      cg04150495 29,7159632 MIR663 TSS1500 
      cg15100599 29,6789583 SUSD4 TSS1500 
      cg16043357 29,6515349 VAX1 TSS200 
      cg00556112 29,6181478 DRD4 TSS200 
      cg02885007 29,6147025 HOXD9 1stExon 
      cg10344081 29,6018833 CDKL2 TSS200 
      cg08074851 29,6002859 KCNK12 TSS200 
      cg23625660 29,5881099 FBXL21 5'UTR 
      cg04510874 29,5812879 FES TSS1500; 5'UTR 
     cg22815110 29,5761915 FOXD3 1stExon 
      cg12338417 29,522526 TRIM71 1stExon 
      cg12058947 29,5220447 HDGFRP3 1stExon 
      cg14013195 29,504343 C2orf39 TSS200 
      cg02583525 29,5009797 C2orf39 TSS200 
      cg07068756 29,4299301 UCHL1 1stExon; 5'UTR 
     cg08109815 29,4131602 NMBR 1stExon; 5'UTR 
     cg04158367 29,4046798 GFI1 TSS1500; TSS200 
     cg10603275 29,3661951 CHL1 5'UTR 
      cg03740978 29,3616401 KCTD1 5'UTR; 1stExon 
     cg20447655 29,3264215 CTHRC1 TSS200 
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cg27147819 29,319036 NKX2-4 TSS200 
      cg13530938 29,3172311 LOC643387 TSS200 
      cg21384402 29,31128 INA TSS1500 
      cg11293190 29,3084176 PLK5P TSS1500 
      cg21270860 29,2263987 POU3F1 TSS1500 
      cg22900415 29,2183155 GJA3 TSS1500 
      cg17988546 29,1968651 MS4A13 1stExon; 5'UTR 
     cg17411190 29,1366777 CLDN5 1stExon 
      cg26563200 29,118973 TEX101 5'UTR; 1stExon 
     cg23290344 29,1111924 NEFM 1stExon; TSS1500 
     cg15600488 29,0374377 MTMR7 TSS200 
      cg16263367 29,0288103 LOC147804; ZNF761 TSS200; TS200 
     cg19779211 28,9991063 KCNQ1 TSS1500 
      cg21200656 28,9937331 NKX2-4 TSS200 
      cg26931862 28,9632596 HOXC12 1stExon 
      cg05386493 28,8878913 C3orf72; FOXL2 TSS1500; 5'UTR; 1stExon 
     cg10888031 28,8788996 ACTRT2 1stExon 
      cg15092343 28,8619453 MSX1 TSS1500 
      cg20800509 28,8415171 RIMS2 5'UTR; 1stExon 
     cg21800232 28,8205092 ANKRD34B TSS200 
      cg16038120 28,7998183 FOXG1 TSS1500 
      cg12175729 28,7970089 KCNK9 TSS1500 
      cg02831587 28,7943174 FAR1 TSS200 
      cg22881914 28,785003 NID2 TSS1500 
      cg03326059 28,7634941 FAR1 TSS200 
      cg23244790 28,7476845 PCDHGA12 1stExon 
      cg16281276 28,7022797 CYB5R2 TSS1500 
      cg21290042 28,666871 CNIH3 TSS200 
      cg16980360 28,6530519 RNF135 1stExon 
      cg11429969 28,6400024 PCDHA3 1stExon 
      cg25335544 28,6390494 CAMKV 5'UTR; 1stExon 
     cg03811478 28,5533904 SOX14 1stExon 
      cg23034757 28,5517061 PCDHGB6 1stExon 
      cg06410537 28,5498721 TLX3 1stExon 
      cg27262412 28,5102817 TBX15 5'UTR 
      cg10776919 28,4391052 DMRTA2 TSS1500 
      cg16132520 28,4286214 AKR1B1 TSS200 
      cg02466113 28,3598176 CDKL2 TSS200 
      cg05040544 28,3575298 EFNB2 TSS1500 
      cg27043726 28,3554963 SNX31 1stExon; 5'UTR 
     cg21643403 28,3039024 CTHRC1 5'UTR; 1stExon 
     cg02694427 28,3033741 HOXD12 TSS200 
      cg09656389 28,2927779 PAX6 TSS1500 
      cg20443254 28,2663048 ASCL4 1stExon 
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